Tag: oncology

Enhertu Is Now FDA-Approved for HER2-Positive Early Breast Cancer Before and After Surgery. Here Is What the DESTINY-Breast11 and DESTINY-Breast05 Data Shows.

✅ Updated May 19, 2026: FDA Approval Confirmed On May 15, 2026, the FDA approved two new indications for Enhertu (fam-trastuzumab deruxtecan-nxki, T-DXd) in adults with HER2-positive early-stage breast cancer. This post has been updated throughout to reflect both approvals. For related coverage of Enhertu’s approved indications in metastatic HER2-positive and HER2-low breast cancer, and how this new approval extends Enhertu into the curative-intent setting, see our companion post on Dato-DXd in triple-negative breast cancer for context on the broader ADC landscape.

📌 The essentials: Two approvals, two different clinical situations Indication 1: Neoadjuvant (before surgery) FDA approved Enhertu followed by THP (taxane, trastuzumab, pertuzumab) for adults with HER2-positive (IHC 3+ or ISH+) stage II or III breast cancer before surgery. Dose: 5.4 mg/kg IV every 3 weeks for 4 cycles, then THP for 4 cycles, then surgery. Clinical basis: DESTINY-Breast11 (NCT05113251): pCR rate 67.3% with T-DXd plus THP versus 56.3% with standard anthracycline-based ddAC-THP (absolute improvement +11.2%; p=0.003). Indication 2: Adjuvant (after surgery, for residual disease) FDA approved Enhertu for adults with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease after neoadjuvant HER2-targeted treatment. Dose: 5.4 mg/kg IV every 3 weeks for a maximum of 14 cycles. Clinical basis: DESTINY-Breast05 (NCT04622319): T-DXd reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 (Kadcyla) (HR 0.47; 95% CI 0.34 to 0.66; p less than 0.0001). Three-year invasive disease-free survival (iDFS): 92.4% versus 83.7%. Key safety note: the label carries a boxed warning for interstitial lung disease (ILD) and pneumonitis. ILD rate was 4.4% in DESTINY-Breast11 and approximately 10% in DESTINY-Breast05. Additional warnings: neutropenia and left ventricular dysfunction.

When a woman is diagnosed with HER2-positive breast cancer, the weeks between diagnosis and surgery are not a waiting period. They are a treatment window, one that oncologists have spent decades trying to use more aggressively and more effectively. The drugs given before surgery, in the neoadjuvant setting, have the opportunity to shrink the tumor, treat any cancer that may have spread to lymph nodes or beyond, and ideally produce an outcome that changes what surgery looks like and what long-term prognosis looks like.

That neoadjuvant window has been anchored to anthracycline-containing chemotherapy regimens for more than a decade. Anthracyclines work, but they carry a burden: cardiac toxicity, hematologic toxicity, significant treatment interruptions. The question oncologists have been asking is whether something better is now available.

On May 18, 2026, the FDA is expected to rule on exactly that question. The drug at the center of the decision is Enhertu (trastuzumab deruxtecan, T-DXd), an antibody-drug conjugate that has already redefined outcomes in metastatic breast cancer. The clinical trial behind the application, DESTINY-Breast11, is the first positive global registrational trial for a new neoadjuvant agent in HER2-positive early breast cancer in over a decade. The data makes a compelling case. Understanding what it actually shows, and what it doesn’t yet tell us, is what this post is for.

HER2-Positive Breast Cancer and the Neoadjuvant Treatment Window

HER2 (human epidermal growth factor receptor 2) is a protein that promotes cell growth. In approximately 15 to 20% of breast cancers, the HER2 gene is amplified, producing too many HER2 receptors on tumor cell surfaces and driving aggressive cancer growth. HER2-positive breast cancer tends to grow faster than hormone receptor-positive cancer but is also more sensitive to HER2-targeted therapies.

Neoadjuvant therapy refers to systemic treatment given before surgery. This is different from adjuvant therapy, which is given after surgery to reduce recurrence risk. In HER2-positive early breast cancer, neoadjuvant treatment serves several purposes:

It may downstage the tumor, reducing its size and lymph node involvement, potentially enabling less extensive surgery
It allows oncologists to observe the tumor’s response to treatment in real time
It provides important prognostic information that guides post-surgery treatment decisions
Most critically: it creates the opportunity for pathologic complete response, the most meaningful outcome measure in this setting

What is a pathologic complete response (pCR) and why does it matter? A pathologic complete response (pCR) means that when the removed tumor and lymph nodes are examined under a microscope after surgery, no viable invasive cancer cells are found. In DESTINY-Breast11, the pCR definition used was ypT0/is ypN0, meaning no residual invasive cancer in the breast (with allowance for non-invasive in-situ disease) and no cancer in the lymph nodes. pCR is one of the most important prognostic markers in HER2-positive breast cancer. Patients who achieve pCR have substantially lower rates of cancer recurrence and significantly better long-term survival than those with residual disease. The relationship between pCR and survival is why the FDA accepts it as a surrogate endpoint for approval in the neoadjuvant setting. The clinical decision implications extend beyond prognosis. Patients who achieve pCR typically continue with standard adjuvant therapy and may be candidates for less extensive surgery. Patients who do NOT achieve pCR are typically offered additional targeted therapy after surgery (currently, T-DM1/Kadcyla is the standard for residual HER2+ disease) to try to reduce their recurrence risk. Understanding pCR rates is therefore both a survival question and a treatment-planning question.

What Enhertu Is and How It Works

Enhertu (trastuzumab deruxtecan, T-DXd) is an antibody-drug conjugate (ADC), a category of targeted therapy that links a cancer-targeting antibody to a chemotherapy payload. The antibody component is trastuzumab, which has been a cornerstone of HER2-positive breast cancer treatment for decades. The payload is deruxtecan, a topoisomerase I inhibitor chemotherapy. The linker between them is designed to be stable in the bloodstream but cleaved inside tumor cells.

The mechanism creates a guided delivery system. Trastuzumab finds tumor cells expressing HER2 on their surface and binds to them. The ADC is then internalized into the cell, where the linker is cleaved and the deruxtecan payload is released directly inside the cancer cell, causing it to die. A key additional property of T-DXd’s payload is what’s called a bystander effect: some of the released chemotherapy can diffuse into neighboring cancer cells, including those that may not strongly express HER2. This may help explain T-DXd’s activity even in heterogeneous tumors.

T-DXd already has FDA approvals for:

HER2-positive metastatic breast cancer (second-line and beyond)
HER2-low metastatic breast cancer (a broader category defined by lower HER2 expression)
HER2-ultralow metastatic breast cancer
HER2-positive metastatic gastric/gastroesophageal junction cancer
HER2-mutant metastatic non-small cell lung cancer

If the May 18 decision is favorable, the neoadjuvant HER2-positive early breast cancer indication would be added to this list. For context on how ADC technology works in a related breast cancer setting, see our detailed coverage of Dato-DXd and TROPION-Breast02 in triple-negative breast cancer.

The DESTINY-Breast11 Trial: Design and Results

Design

DESTINY-Breast11 (NCT05113251) was a global, multicenter, randomized, open-label Phase 3 trial conducted at 147 sites across 18 countries. It enrolled adults with previously untreated, high-risk HER2-positive early breast cancer, defined as tumors that were either T3 or larger with any nodal status, or any T stage with N1 to N3 nodal involvement (node-positive disease), including inflammatory breast cancer. The HER2-positive definition required either IHC 3+ or positive in situ hybridization. Patients were randomized in a 1:1:1 design across three arms:

T-DXd monotherapy arm: T-DXd 5.4 mg/kg every 3 weeks for 8 cycles (n=286), closed early
T-DXd-THP arm: T-DXd 5.4 mg/kg every 3 weeks for 4 cycles, then paclitaxel plus trastuzumab plus pertuzumab (THP) for 4 cycles (n=321)
ddAC-THP (control arm): Dose-dense doxorubicin plus cyclophosphamide every 2 weeks for 4 cycles, then THP for 4 cycles (n=320)

The T-DXd monotherapy arm was closed early in March 2024, following an Independent Data Monitoring Committee recommendation based on lower pCR rates than the combination arms and low likelihood of demonstrating superiority. This was a pre-specified adaptive design decision, not a safety signal.

Primary endpoint: pCR results

Outcome	T-DXd plus THP (n=321)	ddAC plus THP (n=320)
pCR rate (ypT0/is ypN0)	67.3%	56.3%
Absolute difference in pCR	+11.0 percentage points	—
p-value	0.003	—
Patients proceeding to surgery	97.2%	Comparable
EFS HR (immature, 4.5% events)	0.56 (95% CI 0.26 to 1.17)	Reference

Source: Harbeck N et al. Annals of Oncology. 2025. doi:10.1016/S0923-7534(25)04968-3. Presented at ESMO Congress 2025, Berlin. Abstract 291O.

The 11-point improvement in pCR rate is clinically meaningful by any standard in this disease. To put it in context: with existing standard-of-care regimens, pCR rates in high-risk HER2-positive disease range from approximately 39 to 64% depending on population characteristics and regimen. The DESTINY-Breast11 control arm (56.3%) sits in the middle of that range, reflecting an appropriately representative benchmark. The T-DXd-THP arm’s 67.3% is at the top of and above that historical range.

The benefit was consistent across pre-specified subgroups, including both hormone receptor-positive and hormone receptor-negative tumors, an important finding because HER2+/HR+ tumors historically have lower pCR rates and represent a more challenging treatment population.

What about long-term survival?

The EFS (event-free survival) hazard ratio of 0.56 suggests a 44% reduction in the rate of recurrence or death events in favor of T-DXd-THP numerically. However, EFS data maturity was only 4.5% at the time of the analysis, meaning very few events had occurred. The confidence interval (0.26 to 1.17) crosses 1.0, meaning the survival benefit is directionally promising but not yet statistically confirmed.

This is expected and appropriate for a neoadjuvant trial in early-stage cancer: these patients were diagnosed at a potentially curable stage, and survival events take years to accumulate. The FDA’s precedent for accepting pCR as a surrogate endpoint in the neoadjuvant setting means approval does not require mature survival data. More mature EFS and overall survival data from DESTINY-Breast11 will emerge over subsequent years and will be critical for confirming the long-term value of the pCR benefit.

Safety: Better Tolerability Than the Current Standard, With One Key Signal to Monitor

One of the most striking findings in DESTINY-Breast11 is not the efficacy. It is the safety comparison. The T-DXd-THP arm had substantially fewer severe adverse events than the anthracycline-based control.

Safety Metric	T-DXd plus THP	ddAC plus THP
Grade 3 or higher adverse events	37.5%	55.8%
Serious adverse events	10.6%	20.2%
Treatment interruptions	37.8%	54.5%
Left ventricular dysfunction (all grade)	1.3%	6.1%
ILD/pneumonitis (all grade)	4.4%	5.1%
Grade 3/4 ILD events	1	5
Grade 5 (fatal) ILD events	1	1
Treatment-related deaths (all causes)	1 (0.3%)	2 (0.6%)
Most common Grade 3 or higher AE	Neutropenia (13.8%)	Hematologic toxicity predominant
Fatigue (all grade)	41.3%	54.8%

The cardiac finding warrants specific emphasis. Doxorubicin (the “A” in AC chemotherapy) is associated with dose-dependent cardiotoxicity, including cardiomyopathy and heart failure, that can emerge during treatment and persist or worsen years later. The 6.1% rate of left ventricular dysfunction in the control arm versus 1.3% in the T-DXd-THP arm represents a clinically important difference in a population that will be living with the long-term consequences of treatment for decades.

The ILD signal: the key safety consideration for T-DXd Interstitial lung disease (ILD), inflammation and scarring of lung tissue, is the most important safety concern with T-DXd across all its indications. In DESTINY-Breast11, the all-grade ILD rate was 4.4% in the T-DXd-THP arm and 5.1% in the control arm, which are comparable. Most events were Grade 1 or 2 and manageable with dose modification and corticosteroids. However, there was one Grade 5 (fatal) ILD event in each arm, with the independent adjudication committee attributing one death in the T-DXd-THP arm to drug-related pneumonitis. This is not a reason to avoid the drug; one in each arm is a roughly comparable rate at this sample size. But ILD monitoring is a critical clinical requirement for T-DXd in practice. Current guidance requires baseline pulmonary assessment before starting T-DXd, prompt evaluation of any new or worsening respiratory symptoms (dyspnea, cough, fever), immediate T-DXd interruption if ILD is suspected, and corticosteroid treatment for confirmed cases. Providers switching to this regimen must be familiar with ILD surveillance protocols.

What This Means for Patients Navigating Treatment Right Now

If you have been diagnosed with HER2-positive breast cancer at stage II or III and are at the stage of discussing neoadjuvant treatment options with your oncologist, this FDA decision is directly relevant to your care.

If the FDA approves on May 18

T-DXd followed by THP would become an FDA-approved option for high-risk (stage II/III) HER2-positive early breast cancer, specifically for patients with node-positive disease (N1 to N3) or large tumors (T3 or larger).
Your oncologist may recommend this regimen over the current anthracycline-based standard, particularly if your tumor characteristics suggest high risk and you have cardiovascular risk factors that make doxorubicin’s cardiac effects a concern.
The treatment involves 4 cycles of T-DXd (intravenous, every 3 weeks), followed by 4 cycles of paclitaxel plus trastuzumab plus pertuzumab, then surgery. Post-surgery treatment depends on whether you achieved pCR.
If you have already started a neoadjuvant regimen: do not switch without discussion with your oncologist. Mid-treatment changes are complex and require careful individual assessment.

The treatment pathway after surgery

pCR does not mean treatment is finished. Patients who achieve pCR after neoadjuvant therapy typically continue with adjuvant trastuzumab with or without pertuzumab, and those with HR+ disease also receive endocrine therapy. Patients who do NOT achieve pCR currently receive adjuvant ado-trastuzumab emtansine (T-DM1/Kadcyla) to address the residual disease that proved resistant to neoadjuvant treatment.

A higher pCR rate means more patients entering that post-surgery phase in the most favorable prognostic position. For patients who still have residual disease, the adjuvant escalation pathway remains unchanged by this approval.

For related context on ADC mechanisms and how different ADCs work across breast cancer subtypes, see our post on vepdegestrant and the PROTAC mechanism in ESR1-mutated ER+ breast cancer and our analysis of Dato-DXd in triple-negative breast cancer.

Reading This Honestly: Context and Limitations

Survival data is immature

At 4.5% EFS maturity, we do not yet have confirmatory evidence that the pCR improvement translates into longer survival. The FDA’s precedent allows pCR as a surrogate, and the EFS directional signal (HR 0.56) is encouraging, but it is not yet proven. Patients and oncologists making decisions now are extrapolating from a strong surrogate, not from confirmed survival benefit. The maturing EFS and OS data from DESTINY-Breast11 will be the most important data to watch over the next several years.

Representation limitations

The published trial report specifically notes under-representation of Black or African American patients. This is a meaningful limitation in a disease where Black women are more likely to be diagnosed with aggressive subtypes and at advanced stages, and where outcomes disparities are well documented. Whether the pCR and safety results generalize fully to this population requires additional study and real-world evidence.

The monotherapy arm closed early

T-DXd monotherapy (without the THP sequence) achieved pCR rates of 43 to 51%, which is numerically inferior to both the combination arm and the control arm. The IDMC closed enrollment in that arm based on this finding. The approved regimen, if cleared, will be T-DXd followed by THP, not T-DXd alone. This distinction matters for clinical implementation.

What Happens on and After May 18

The PDUFA date is May 18, 2026. This is the deadline by which the FDA must complete its review. Decisions can come on or before this date.

If approved, T-DXd followed by THP would immediately be available to prescribers as the first ADC-based neoadjuvant regimen for HER2-positive early breast cancer. NCCN guideline updates and payer coverage decisions typically follow relatively quickly for priority FDA approvals, though individual insurance authorization timelines vary.

China has already approved this regimen based on the same DESTINY-Breast11 data. The European Medicines Agency review is ongoing. Regulatory validation across multiple agencies, if it follows, will strengthen the evidence base further.

We will update this post when the FDA’s ruling is announced.

Are you or a family member navigating a HER2-positive breast cancer diagnosis?

Treatment decisions in early breast cancer are among the most consequential and time-sensitive in oncology. If you have been recently diagnosed with HER2-positive stage II or III breast cancer, the most important step is consultation with a breast oncologist at a cancer center with expertise in HER2-directed therapies and access to current clinical trial data. The NCI-Designated Cancer Centers directory maintains a searchable list of specialized breast oncology programs. Susan G. Komen and the Metastatic Breast Cancer Alliance maintain patient navigation resources. We will continue tracking the FDA’s decision and the maturing DESTINY-Breast11 survival data as both become available.

Sources

Primary trial publication: Harbeck N et al. Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial. Annals of Oncology. 2025. doi:10.1016/S0923-7534(25)04968-3

PubMed: Harbeck N et al. DESTINY-Breast11. PubMed. PMID: 41130363.

ESMO 2025 abstract: Harbeck N et al. DESTINY-Breast11: Neoadjuvant T-DXd alone or followed by THP vs SOC for high-risk HER2+ eBC. ESMO Congress 2025. Abstract 291O.

DESTINY-Breast11 trial registration: NCT05113251. ClinicalTrials.gov.

AstraZeneca/Daiichi Sankyo press release: Enhertu followed by THP before surgery resulted in a pathologic complete response in 67% of patients in DESTINY-Breast11 Phase III trial. astrazeneca.com. October 18, 2025.

Targeted Oncology trial coverage: DESTINY-Breast11: Neoadjuvant T-DXd/THP Improves pCR in High-Risk HER2+ BC. targetedonc.com. October 2025.

FDA surrogate endpoint resource: Surrogate Endpoint Resources for Drug and Biologic Development. FDA.gov.

T-DM1 FDA approval: FDA approves ado-trastuzumab emtansine for HER2-positive breast cancer. FDA.gov.

Patient resources: NCI Cancer Center directory | Susan G. Komen | MBC Alliance | NCCN Breast Cancer Guidelines

Disclaimer: Health Evidence Digest provides general information about clinical trials and FDA regulatory processes for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about breast cancer treatment, including neoadjuvant therapy, should be made in close consultation with a qualified oncologist who can account for your individual diagnosis, tumor characteristics, and health status.

May 19, 2026

The First BCL-2 Inhibitor Specifically Approved for Mantle Cell Lymphoma Just Received FDA Clearance. Here Is What the Data Shows.

📌 The essentials Drug: Beqalzi (sonrotoclax) — a next-generation, highly selective BCL-2 inhibitor. FDA approval type: Accelerated approval on May 13, 2026. Continued approval may depend on confirmatory clinical trial results. Developer: BeOne Medicines USA, Inc. (formerly BeiGene). Indication: Adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two prior lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. What makes it first-in-class: First and only BCL-2 inhibitor specifically approved for MCL. Venetoclax (Venclexta) is approved for CLL and AML but not MCL. Key trial results (BGB-11417-201, n=103): ORR 52% (95% CI 42–62%), median duration of response 15.8 months, median time to response 1.9 months. Dosing: Oral tablet, once daily with food, following a 4-week dose ramp-up schedule. Target dose: 320 mg once daily. Critical warning: Tumor lysis syndrome (TLS) — potentially life-threatening. Requires risk assessment, prophylaxis, and close monitoring throughout the ramp-up phase. Regulatory designations: Breakthrough Therapy, Fast Track, Orphan Drug, Priority Review. Reviewed under Project Orbis.

Mantle cell lymphoma does not follow the forgiving course of many lymphoma subtypes. It is aggressive. It responds to first-line therapy in many patients, but it almost always comes back. After a first relapse on BTK inhibitor therapy, which has been the most important treatment advance in MCL over the past decade, options narrow considerably. Response rates with available agents are often modest. Duration of response can be brief. A population of patients with limited alternatives and deteriorating disease has been waiting for something new to try.

On May 13, 2026, the FDA granted accelerated approval to Beqalzi (sonrotoclax) for adults with relapsed or refractory MCL after at least two prior lines of therapy including a BTK inhibitor. Beqalzi is a BCL-2 inhibitor, and it is the first drug in that class specifically approved for mantle cell lymphoma. The pivotal trial in 103 patients showed a 52% overall response rate and a median duration of response of 15.8 months, with a notably high response rate in TP53-mutant patients who typically fare poorly with existing options.

Mantle Cell Lymphoma: Why Post-BTK Relapse Is Such a Difficult Problem

Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma that originates in the mantle zone of the lymph node. It accounts for approximately 5% of non-Hodgkin lymphoma cases globally, with roughly 3,300 new diagnoses annually in the United States. The median age at diagnosis is approximately 65, and the disease is more common in men.

MCL is characterized biologically by the t(11;14) chromosomal translocation, which places the CCND1 gene encoding cyclin D1 under the control of an immunoglobulin heavy chain promoter, driving overexpression of cyclin D1 and uncontrolled cell proliferation. Most MCL tumors also dysregulate the BCL-2 anti-apoptotic pathway, which helps cancer cells survive even when they should die. These two biological features, the proliferative driver and the survival mechanism, are both targets for therapy.

BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) transformed the treatment of MCL at first and second relapse, producing high response rates in the 70-80% range. But responses are not permanent. Most patients eventually progress on BTK inhibitor therapy. At that point, the disease has developed resistance mechanisms, the patient has typically accumulated treatment-related organ stress, and available next-line options have produced response rates in the 20-40% range with short durations.

TP53 mutations: the highest-risk subgroup in MCL TP53 encodes p53, the tumor suppressor protein that normally triggers cell death when DNA damage occurs. TP53 mutations are present in approximately 20–30% of MCL patients and are strongly associated with chemotherapy resistance, shorter remission durations, and worse overall survival. Patients with TP53-mutant MCL represent one of the highest-unmet-need populations in hematologic oncology. Standard chemotherapy regimens, which work partly through DNA damage that requires functional p53 to trigger apoptosis, are less effective when p53 is mutated. In the BGB-11417-201 trial supporting Beqalzi’s approval, the TP53-mutant subgroup achieved an ORR of 59.1%, numerically higher than the 52% overall population response rate. This is the opposite of what is typically seen with chemotherapy-based regimens in this subgroup, and it supports the mechanistic hypothesis that BCL-2 inhibition can bypass p53-dependent pathways to induce cancer cell death.

How BCL-2 Inhibition Works and What Makes Sonrotoclax Different from Venetoclax

BCL-2 (B-cell lymphoma 2) is a protein that promotes cell survival by blocking apoptosis, the programmed cell death process that the body uses to eliminate damaged, aged, or abnormal cells. In normal cells, BCL-2 is part of a balanced system of pro- and anti-apoptotic proteins. In many B-cell malignancies, BCL-2 is overexpressed, tipping the balance toward survival and allowing cancer cells to accumulate rather than die.

BCL-2 inhibitors work by occupying the BH3-binding groove of the BCL-2 protein and displacing the pro-apoptotic proteins it normally sequesters. When these pro-apoptotic proteins are released, they activate the mitochondrial apoptosis cascade, triggering cell death. This mechanism is independent of TP53 function, which explains why BCL-2 inhibitors can be active in TP53-mutant tumors that resist DNA-damaging chemotherapy.

Sonrotoclax versus venetoclax

Venetoclax (Venclexta) is the established BCL-2 inhibitor in the market, approved for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). It has been used off-label in MCL with modest activity. Sonrotoclax was engineered with greater potency and selectivity for BCL-2 compared to venetoclax, targeting BCL-2 more precisely while having less activity against the related BCL-XL protein.

Feature	Sonrotoclax (Beqalzi)	Venetoclax (Venclexta)
BCL-2 selectivity	Higher selectivity for BCL-2; reduced BCL-XL activity	BCL-2 selective; BCL-XL activity also noted
FDA-approved for MCL	Yes — May 13, 2026 (accelerated)	No — approved for CLL and AML only
Approved indications	R/R MCL after ≥2 lines including BTK inhibitor	CLL (with obinutuzumab or ibrutinib), R/R AML (with azacitidine or decitabine)
Target dose	320 mg once daily (after 4-week ramp-up)	400 mg once daily (after 5-week ramp-up for CLL)
Tumor lysis syndrome risk	Yes — requires ramp-up and prophylaxis	Yes — requires ramp-up and prophylaxis
Route	Oral, once daily with food	Oral, once daily with food

The BGB-11417-201 Trial: Design and Results

Trial design

BGB-11417-201 (NCT05471843) is a single-arm, multicenter, open-label Phase 1/2 trial. Part 1 established the safety, tolerability, and recommended Phase 2 dose (RP2D) of sonrotoclax through dose escalation. No dose-limiting toxicities were observed during this phase, and 320 mg once daily was identified as the RP2D. Part 2 evaluated sonrotoclax at the 320 mg RP2D following a 4-week dose ramp-up schedule in patients with relapsed or refractory MCL.

Eligibility for the efficacy-evaluable population required: histologically confirmed MCL, at least one prior anti-CD20-based therapy, at least one prior BTK inhibitor, ECOG performance status 0-2, adequate organ function, and no prior BCL-2 inhibitor therapy.

Efficacy results

Endpoint	Result
Study population (Part 2)	103 adults with R/R MCL; median age 68; all received prior anti-CD20 and BTK inhibitor
Prior lines of therapy (median)	3 (range 2–9)
Overall response rate (ORR)	52% (95% CI 42–62%; 1-sided p<0.0001)
Complete response (CR) rate	15.5% (95% CI 9.1–24.0%)
Partial response (PR) rate	36.9%
Median time to first response	1.9 months (range 1.6–6.2 months)
Median duration of response (DOR)	15.8 months (95% CI 7.4 months to not estimable)
Median follow-up (efficacy analysis)	11.9 months (per IRC) / 14.2 months (per Targeted Oncology)
TP53-mutant subgroup ORR	59.1%
Assessment method	Independent review committee (IRC) using Lugano criteria

Source: FDA press release May 13, 2026. AJMC, ASCO Post, CancerNetwork, Targeted Oncology. BGB-11417-201, NCT05471843.

A 52% ORR in a heavily pre-treated population, many of whom had BTK inhibitor-resistant disease after a median of three prior lines of therapy, is a meaningful result. The 15.8-month median DOR is also notable in a disease where post-BTK responses often last only a few months. The upper bound of the DOR confidence interval (not estimable) at a median follow-up of approximately 12 months suggests that a proportion of responses were still ongoing at the time of analysis.

The TP53-mutant subgroup ORR of 59.1% is the most clinically significant finding for oncologists. Standard chemotherapy regimens are typically less effective in TP53-mutant MCL, and a response rate numerically higher in this subgroup than in the overall population suggests that BCL-2 inhibition may offer the most value precisely where current options are least effective.

What accelerated approval means for this drug The FDA’s accelerated approval pathway allows earlier approval of drugs for serious conditions based on a surrogate endpoint (in this case, ORR and DOR) that is reasonably likely to predict clinical benefit, while requiring the sponsor to conduct confirmatory trials demonstrating actual clinical benefit such as overall survival. For Beqalzi, continued approval may depend on the results of confirmatory studies. BeOne Medicines is conducting a broader clinical program for sonrotoclax, including combination studies with BTK inhibitors (notably zanubrutinib, also a BeOne Medicine product) in MCL and other B-cell malignancies. If those studies demonstrate clinical benefit, the accelerated approval pathway to full approval becomes available. For patients with relapsed or refractory MCL who have exhausted prior lines of therapy, accelerated approval provides access to an investigational drug that has demonstrated meaningful activity now, rather than waiting for the confirmatory trial to complete. This is the intended purpose of the pathway for serious, life-threatening conditions.

Safety: The TLS Warning That Requires Proactive Management

Tumor lysis syndrome: the primary safety concern

Tumor lysis syndrome is the most serious safety concern for Beqalzi, shared with venetoclax and other potent agents that rapidly kill large numbers of cancer cells. When cancer cells die quickly, they release their contents into the bloodstream: potassium, phosphate, nucleic acids, and uric acid. The kidneys may not be able to clear this influx quickly enough, leading to a metabolic emergency that can cause kidney failure, life-threatening cardiac arrhythmias, seizures, and death.

Beqalzi’s prescribing information requires the following TLS management steps:

Pre-treatment risk assessment: Evaluate the patient’s baseline risk of TLS based on tumor bulk, renal function, and uric acid levels before starting Beqalzi.
Prophylactic hydration: Patients should drink 6 to 8 glasses (approximately 1.5 to 2 liters) of water daily starting 1 to 2 days before the first dose, on the day of the first dose, on any day the dose is increased, and when restarting treatment.
Anti-hyperuricemic agents: Healthcare providers may prescribe allopurinol or rasburicase before and during the dose ramp-up to reduce uric acid levels.
Blood monitoring: Blood tests for TLS markers (potassium, phosphate, uric acid, creatinine) are required before and during treatment, especially during the 4-week ramp-up.
4-week ramp-up schedule: Doses are increased stepwise over 4 weeks to reach the 320 mg target dose, reducing the rate of cell death at any one time and lowering TLS risk. Strong CYP3A inhibitors are contraindicated during the ramp-up phase as they increase sonrotoclax exposure.

Other important safety findings from the trial

Serious adverse reactions occurred in 37% of patients in the trial, with pneumonia the most common serious adverse reaction at 10%. Grade 3 or 4 laboratory abnormalities occurring in at least 15% of patients included decreased lymphocyte counts and decreased neutrophil counts. The most common adverse reactions overall were pneumonia, fatigue, edema, diarrhea, and upper respiratory tract infection.

The prescribing information also carries warnings for serious infections (including fatal infections) and neutropenia, both of which require monitoring. Patients on Beqalzi who develop fever, chills, or other signs of infection should contact their oncology team promptly.

Beqalzi carries an embryo-fetal toxicity warning. Women of childbearing potential and male patients with female partners who could become pregnant must use effective contraception during treatment and for one week after the last dose.

Dosing and Administration: The 4-Week Ramp-Up Schedule

Ramp-up week	Daily dose	Key requirement
Week 1 (days 1–7)	20 mg once daily	TLS monitoring; avoid strong CYP3A inhibitors
Week 2 (days 8–14)	80 mg once daily	TLS monitoring; hydration continued
Week 3 (days 15–21)	160 mg once daily	Blood tests for TLS markers
Week 4 (days 22–28)	240 mg once daily	Continue monitoring
Week 5 onward	320 mg once daily	Target dose reached; once-daily dosing with food continues

Beqalzi tablets are available in four strengths (1 mg, 5 mg, 20 mg, and 80 mg) to allow precise dosing throughout the ramp-up schedule. All doses should be taken with food. If a dose is missed and it is more than 8 hours since the scheduled time, skip that dose and take the next scheduled dose at the regular time.

The CYP3A inhibitor contraindication during ramp-up: a clinically important interaction Sonrotoclax is metabolized by CYP3A4. Strong CYP3A inhibitors, including azole antifungals (fluconazole, voriconazole, itraconazole), certain macrolide antibiotics (clarithromycin), and HIV protease inhibitors, significantly increase sonrotoclax exposure. This dramatically increases TLS risk during the ramp-up phase when doses are already being escalated. Starting Beqalzi or increasing the dose while a patient is taking a strong CYP3A inhibitor is contraindicated. Moderate CYP3A inhibitors require dose reduction. Patients and prescribers should review all concomitant medications carefully before initiating and during the ramp-up phase. If a patient needs to restart Beqalzi after a treatment break, the full ramp-up schedule must be repeated. This is an important point for patients who interrupt treatment due to adverse events or procedures.

🔗 Also on HED: The FDA’s Real-Time Clinical Trials Initiative: AstraZeneca’s TRAVERSE Trial Involves the Same Drug Class Our post on the FDA’s April 2026 real-time clinical trials pilot covers the TRAVERSE trial, which studies acalabrutinib + venetoclax + rituximab in treatment-naive MCL at MD Anderson and UPenn. The combination of BTK inhibition and BCL-2 inhibition in the same patient population where Beqalzi is now approved for later lines illustrates how the MCL treatment landscape is being built out.

What This Means for Patients with Relapsed Mantle Cell Lymphoma

Beqalzi is specifically for patients who have already received at least two prior lines of therapy including a BTK inhibitor. It is not a first-line or second-line therapy. For patients currently in earlier stages of MCL treatment, this approval does not change the immediate treatment path.

For patients who have received both a chemoimmunotherapy regimen and a BTK inhibitor and whose disease has progressed, Beqalzi now provides an FDA-approved BCL-2 inhibitor option with a 52% response rate and a median response duration of 15.8 months in a clinical trial population that closely reflects this setting.

Questions to discuss with your hematologist or oncologist if you or a family member is in this situation:

Am I eligible for Beqalzi based on my treatment history? The requirement is at least two prior lines including a BTK inhibitor, with no prior BCL-2 inhibitor.
What is my TLS risk profile, and what monitoring and prophylaxis will I need before and during the ramp-up?
Are there clinical trials of sonrotoclax in combination with other agents that might be appropriate for my specific situation?
Are there confirmatory trials I could participate in that would contribute to the evidence base for this drug?

Resources for patients with mantle cell lymphoma

For patients navigating MCL treatment decisions, the Lymphoma Research Foundation maintains patient education resources on MCL specifically, including information on clinical trial participation. The NCI’s Cancer Center directory can help identify centers with dedicated lymphoma programs and access to the newest approved therapies. For Beqalzi specifically, BeOne Medicines’ patient support program information will be available through the treating oncologist or hematologist at prescribing.

Sources

FDA accelerated approval announcement: FDA grants accelerated approval to sonrotoclax (Beqalzi) for relapsed or refractory mantle cell lymphoma. FDA.gov. May 13, 2026.

AJMC coverage: Sonrotoclax Granted Accelerated Approval for R/R Mantle Cell Lymphoma. ajmc.com. May 13, 2026.

Hematology Advisor: FDA Grants Accelerated Approval to Beqalzi for R/R Mantle Cell Lymphoma. hematologyadvisor.com. May 2026.

OncLive: FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell Lymphoma. onclive.com. May 13, 2026.

CancerNetwork: FDA Approves Sonrotoclax in Relapsed/Refractory Mantle Cell Lymphoma. cancernetwork.com. May 2026.

Targeted Oncology: FDA Approves Next-Gen BCL2 Inhibitor Sonrotoclax for R/R Mantle Cell Lymphoma. targetedonc.com. May 2026.

CURE Today: FDA Approves Beqalzi for Relapsed Mantle Cell Lymphoma. curetoday.com. May 2026.

ASCO Post: Sonrotoclax Receives Accelerated Approval in Relapsed or Refractory MCL. ascopost.com. May 2026.

Oncology Nursing News: FDA Approves Sonrotoclax for R/R Mantle Cell Lymphoma. oncnursingnews.com. May 2026.

Drugs.com drug information: Beqalzi (sonrotoclax): Uses, Dosage, Side Effects, Warnings. drugs.com.

Trial registration: BGB-11417-201. A Study of Sonrotoclax (BGB-11417) in Participants With B-Cell Malignancies. NCT05471843. clinicaltrials.gov.

Patient resources: Lymphoma Research Foundation: lymphoma.org; NCI Cancer Centers: cancer.gov/research/nci-role/cancer-centers

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Beqalzi is approved under the accelerated approval pathway, and continued approval may depend on confirmatory trial results. All treatment decisions for mantle cell lymphoma should be made in close consultation with a qualified hematologist or oncologist.

May 18, 2026

A New Device for Detecting Uterine Cancer in the Doctor’s Office Just Received FDA Clearance. Here Is Who Should Know About It.

Uterine cancer is the most common gynecologic malignancy in the United States. This year, an estimated 68,270 women will receive a new diagnosis of endometrial carcinoma, the most common type. Death rates from the disease have been rising steadily since 1997, and the gap between early-stage survival (up to 95%) and late-stage survival (below 20%) is among the widest of any cancer. The difference between those two outcomes often comes down to whether the cancer was caught before it spread.

Unlike cervical cancer, which has a well-established routine screening test (the Pap smear), endometrial cancer has no recommended population-level screening for average-risk women. Diagnosis depends on evaluating symptoms, primarily abnormal uterine bleeding, and performing an endometrial biopsy when warranted. The current standard device for that biopsy is the Pipelle sampler, a thin plastic catheter that has not fundamentally changed in decades.

On April 22, 2026, Utepreva LLC announced FDA 510(k) clearance for the Utepreva Endometrial Sampler, a redesigned single-use device that combines three collection mechanisms in one instrument and supports cytologic, histopathologic, and molecular testing from a single sample. The company says the procedure takes about 20 seconds and requires no dilation, sedation, or operating room. Providers can order it beginning in October 2026.

Endometrial Cancer: The Disease Most Women Know Least About

The endometrium is the inner lining of the uterus. Each month during a woman’s reproductive years, it thickens in preparation for a potential pregnancy and sheds if conception does not occur. When cells in this lining undergo malignant transformation, the result is endometrial carcinoma, the most common uterine cancer by far.

Most endometrial cancers are diagnosed because a woman reports abnormal uterine bleeding to her gynecologist. In postmenopausal women, any vaginal bleeding is considered abnormal and warrants evaluation. Because this symptom tends to appear when the cancer is still localized to the uterus, endometrial cancer is frequently caught at stage I, when surgical removal is usually curative. The problem is the proportion of women who either dismiss the bleeding, delay seeking care, or are told it is nothing to worry about before receiving a proper evaluation.

The racial disparity in endometrial cancer outcomes Non-Hispanic Black women have the highest mortality rate from uterine cancer of any racial or ethnic group in the United States, and the gap has been widening. Black women are more likely to be diagnosed with aggressive non-endometrioid histologic subtypes (Type II tumors), which account for a disproportionate share of deaths despite representing a minority of total cases. Barriers to timely evaluation, lower rates of specialist access, and differences in tumor biology all contribute. Any advance in detection infrastructure that makes endometrial evaluation faster, less costly, and more accessible in office-based settings has equity implications as well as clinical ones.

Who Is at Risk: A Practical Guide to Endometrial Cancer Risk Factors

Most endometrial cancer risk comes down to one underlying mechanism: prolonged exposure of the uterine lining to estrogen without the counterbalancing effect of progesterone. Conditions that increase this “unopposed estrogen” exposure elevate endometrial cancer risk. Here is what that looks like in practice.

Risk factor	What it means clinically
Postmenopausal bleeding	The most actionable symptom. Any vaginal bleeding after menopause requires evaluation. This alone is an indication for endometrial sampling regardless of other risk factors.
Obesity (BMI 30 or above)	The strongest modifiable risk factor. Excess body fat increases peripheral conversion of androgens to estrogen. Nearly 70% of early-stage endometrial cancer patients are obese.
Estrogen therapy without progestogen	Women with a uterus taking estrogen-only hormone therapy have significantly elevated risk. Combination (estrogen plus progestogen) therapy does not carry the same risk.
Tamoxifen use	Tamoxifen, used in breast cancer treatment and prevention, acts as an estrogen agonist in the uterus even while blocking estrogen in breast tissue. Women on tamoxifen who develop any abnormal uterine bleeding should be evaluated promptly.
Lynch syndrome (hereditary)	Lynch syndrome carriers have a lifetime endometrial cancer risk of 13 to 60%, depending on the gene mutation (MLH1, MSH2, MSH6, PMS2). This is often higher than their colorectal cancer risk. All women with Lynch syndrome should discuss surveillance with their gynecologist.
Nulliparity and late menopause	Women who have never been pregnant and those who experienced menopause after age 55 have had longer cumulative estrogen exposure.
Diabetes and metabolic syndrome	Hyperinsulinemia and insulin resistance promote endometrial cell proliferation independently of estrogen levels.
Age 50 to 70	Incidence peaks in this age range, coinciding with the postmenopausal transition and its associated hormonal changes.
Family history	A first-degree relative with endometrial or colorectal cancer warrants discussion about Lynch syndrome testing even if the patient does not meet formal criteria.

Sources: AAFP (Am Fam Physician. 2025;111(6):526-531), StatPearls Endometrial Cancer, StatPearls Postmenopausal Bleeding.

How Endometrial Cancer Is Currently Diagnosed

When a woman presents with postmenopausal bleeding or other concerning symptoms, the standard evaluation pathway begins with a pelvic examination and often a transvaginal ultrasound to measure endometrial thickness. An endometrial stripe of more than 4 mm in a postmenopausal woman with bleeding is an indication for tissue sampling. Even a stripe below that threshold does not rule out malignancy if bleeding is persistent.

Tissue sampling is performed with an endometrial sampler inserted through the cervix into the uterine cavity. The Pipelle sampler, introduced in the 1980s, remains the most commonly used device in the United States. It is a thin plastic catheter that uses a retractable piston to create suction and aspirate endometrial tissue. It works well in straightforward cases but has documented limitations: it samples a fraction of the uterine cavity, may produce insufficient tissue in certain uterine configurations, and cannot collect the range of sample types (cytologic, histopathologic, molecular) from a single pass that modern testing increasingly requires.

When the Pipelle yields insufficient tissue, or when a focal lesion is suspected, the next step is dilation and curettage (D&C) under sedation or general anesthesia, with or without hysteroscopy. This requires operating room resources, carries anesthesia risk, and adds cost and scheduling delay.

🔗 Also on HED: Vaginal Estrogen Safety in Endometrial Cancer Survivors Our previous post covered a landmark 2,824-patient matched cohort study and the FDA’s February 2026 removal of the boxed warning for vaginal estrogen in endometrial cancer survivors. Relevant background for anyone following uterine cancer care
https://healthevidencedigest.com/vaginal-estrogen-therapy-not-linked-to-cancer-recurrence-in-younger-survivors-of-endometrial-cancer/

What the Utepreva Endometrial Sampler Is and How It Works

The Utepreva Endometrial Sampler (510(k) clearance K240595) is a single-use, patented device that combines three distinct tissue collection mechanisms in one instrument, intended to be performed as a single-pass sampling procedure.

The three mechanisms

Tissue disruption (brush): A brush component at the device tip physically disrupts the endometrial surface to loosen tissue, similar in concept to how a cervical brush works in a Pap smear.
Suction (plunger-driven aspiration): A plunger inside the sheath generates suction that aspirates dislodged cells and tissue into the collection channel, preventing sample loss. This replaces the piston-retraction mechanism of the Pipelle with a more controlled aspiration system.
Sponge absorption: A sponge tip at the device end absorbs fluid and cells from the uterine cavity. This captures material that would not be collected by suction alone, including cells suspended in uterine fluid rather than adherent to the wall.

The device features a slim-profile wand and an integrated cervical guard to prevent over-insertion. The company states the procedure is completed in approximately 20 seconds, requires no cervical dilation, no sedation, and no operating room.

What types of testing the sample supports

Because the device collects tissue through three complementary mechanisms, the resulting sample supports three categories of laboratory analysis from a single collection pass:

Cytologic analysis: examination of individual cells and cell clusters under a microscope, comparable to cervical cytology in a Pap smear.
Histopathologic analysis: examination of tissue architecture and cell morphology in the standard endometrial biopsy format, allowing diagnosis of endometrial hyperplasia, atypical hyperplasia, and carcinoma.
Molecular analysis: biomarker testing including mismatch repair protein immunohistochemistry, Lynch syndrome screening, and other emerging molecular markers that increasingly inform endometrial cancer subtyping and treatment planning.

Artera notes that results are available within one to two days and that the test produces no inconclusive results based on insufficient tissue, which is a relevant distinction: one of the main failpoints of the current Pipelle is producing an insufficient sample that requires a return visit or D&C.

The Preclinical Evidence: What Testing Showed

The FDA clearance was supported by preclinical and design verification testing conducted by Medical Murray, a medical device manufacturer. Testing compared the Utepreva device against a commercially available endometrial sampler using a standardized model of simulated endometrial tissue under controlled conditions.

Under those conditions, the Utepreva device captured a greater volume of simulated tissue and demonstrated more uniform disruption across the sampling surface. The difference in tissue capture was statistically significant. The company has presented the device at the American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting in May 2026.

What the clearance pathway tells us about the evidence standard The FDA cleared Utepreva through the 510(k) pathway, which permits clearance of a medical device if it is substantially equivalent to an already legally marketed device. The Utepreva Endometrial Sampler is substantially equivalent to existing endometrial sampling devices, cleared for the same intended use, which is obtaining endometrial tissue samples for laboratory analysis. 510(k) clearance does not require the same level of clinical efficacy evidence as a PMA (premarket approval) or a drug NDA. The supporting data is preclinical bench testing, not randomized clinical trials in patients. This means the device’s performance in real clinical settings, across diverse patient populations and uterine anatomies, will need to be established through post-clearance use and publication. The absence of peer-reviewed clinical trial data at the time of clearance is a standard feature of most new medical device clearances, not a red flag specific to Utepreva. It is, however, a limitation worth naming clearly for anyone following this device’s evidence trajectory.

What Patients Should Know: Who Needs Endometrial Evaluation and When

There is no routine screening test for average-risk women

Current guidelines from AAFP, ACOG, and the American Cancer Society do not recommend routine endometrial cancer screening in asymptomatic women at average risk. No Pap smear equivalent exists for the endometrium. This means that for most women, the pathway to early diagnosis runs through symptom recognition and timely evaluation, not through a scheduled test.

Report any postmenopausal bleeding promptly

Postmenopausal bleeding is the reason for approximately two-thirds of all gynecologic office visits in postmenopausal women, and it is the single most important early symptom of endometrial cancer. Any bleeding after 12 consecutive months without a period warrants a same-cycle evaluation rather than a wait-and-see approach. Even a single episode of light spotting should be discussed with a gynecologist.

Special situations that warrant proactive discussion

Women with Lynch syndrome should discuss an individualized surveillance plan with their gynecologist. Annual endometrial sampling beginning at age 30 to 35 is considered for Lynch carriers in some guidelines, though the evidence base for specific protocols remains limited.
Women taking tamoxifen should be counseled on endometrial cancer symptoms at each follow-up visit. Any abnormal uterine bleeding should trigger evaluation, even if the ovaries are still functioning.
Women with obesity who are approaching or in the menopause transition have enough baseline risk that any menstrual irregularity outside a normal perimenopause pattern warrants discussion with a provider rather than dismissal.

When will Utepreva be available?

Utepreva LLC has announced the device will be available to healthcare providers beginning in October 2026. Patients will not purchase or use it directly. If your gynecologist performs endometrial sampling in the office, you can ask whether they will be adopting the new device. For now, the Pipelle and similar existing samplers remain the standard of care for in-office endometrial biopsy.

The bottom line

Endometrial cancer is the most common gynecologic cancer in the United States, and it is one where early detection reliably leads to good outcomes. The current diagnostic infrastructure relies on a device that has not been meaningfully updated in decades, and on patients and providers taking postmenopausal bleeding seriously at first presentation. The Utepreva Endometrial Sampler does not change who needs evaluation or when. What it offers, if its preclinical performance translates to clinical practice, is a more comprehensive tissue sample from a single office procedure. Real-world clinical data after the October 2026 launch will determine whether the promise holds. For patients and providers navigating this space today, the most useful resources remain ACOG’s clinical practice guidelines on endometrial cancer evaluation and the American Cancer Society’s endometrial cancer overview.

Sources

Utepreva press release (PR Newswire): Utepreva Introduces FDA 510(k)-Cleared Endometrial Sampler Designed to Support Early Detection of Endometrial Cancer. April 22, 2026.

Contemporary OB/GYN: Utepreva Launches FDA-Cleared Endometrial Sampler to Support Endometrial Cancer Detection. contemporaryobgyn.net. April 2026.

Clinical Lab Products: New Endometrial Sampling Device Receives FDA Clearance for Cancer Detection. clpmag.com. April 2026.

BioSpace: Utepreva Introduces FDA 510(k)-Cleared Endometrial Sampler. biospace.com. April 22, 2026.

FDA 510(k) clearance record: Utepreva Endometrial Sampler (UP01), K240595. FDA.gov.

AAFP Rapid Evidence Review: Endometrial Cancer. Am Fam Physician. 2025;111(6):526-531.

StatPearls (endometrial cancer): Endometrial Cancer. StatPearls. NCBI Bookshelf. Updated 2024.

StatPearls (postmenopausal bleeding): Postmenopausal Bleeding. StatPearls. NCBI Bookshelf. Updated January 2025.

Medscape: Endometrial Carcinoma: Background, Etiology, Epidemiology. emedicine.medscape.com.

ACS uterine cancer statistics: Key Statistics for Uterine Cancer. cancer.org.

HED internal: Vaginal Estrogen Safety in Endometrial Cancer Survivors and the FDA February 2026 Boxed Warning Removal. Health Evidence Digest.

Disclaimer: Health Evidence Digest provides general information about medical devices and health research for educational purposes. This content is not a substitute for professional medical advice. The Utepreva Endometrial Sampler is a cleared medical device, not a diagnostic test or treatment. All decisions about endometrial evaluation and cancer screening should be made in consultation with a qualified gynecologist or healthcare provider.

May 14, 2026

A New AI Tool Can Help Predict Which Breast Cancer Patients Can Skip Chemotherapy. The FDA Just Cleared It.

Chemotherapy works. For many women with breast cancer, it meaningfully reduces the risk that cancer will return. But chemotherapy also causes real harm: nausea, fatigue, increased infection risk, potential cardiac effects, nerve damage, and in some cases long-term consequences that persist years after treatment ends. For decades, oncologists have known that some women with early-stage breast cancer receive chemotherapy even though their tumor biology would never have threatened them with a recurrence. They endure months of treatment and its side effects for a benefit that, statistically, would not have materialized.

The challenge has always been identifying those women reliably, at the time of diagnosis, before any treatment has started. Existing tools like Oncotype DX and MammaPrint already attempt this, but they require separate molecular testing, come with turnaround times of several days, and cost thousands of dollars. The question the field has been working toward: can AI read a standard pathology slide, combine that with basic clinical data, and produce reliable risk stratification at the point of diagnosis, using materials that already exist?

On May 6, 2026, the FDA cleared ArteraAI Breast (Artera) for exactly that purpose. It is the first FDA-cleared digital pathology-based risk stratification tool for breast cancer. The answer, based on validated clinical trial data, is yes.

🔗 Also on HED: AI-Supported Mammography Just Got Its Strongest Evidence Yet This post is part of an ongoing HED series on artificial intelligence in women’s cancer care. Our previous post covered the landmark MASAI trial, which showed AI-supported mammography detected more cancers with no increase in false positives in a 105,000-woman randomized controlled trial.

Who ArteraAI Breast Is For

ArteraAI Breast is cleared for patients with early-stage, hormone receptor-positive (HR+), HER2-negative invasive breast cancer. This is the most common breast cancer subtype, accounting for approximately 70% of all breast cancer diagnoses. The HR+/HER2- designation means the tumor is driven by estrogen or progesterone signaling and does not overexpress HER2. Standard treatment for early-stage disease in this group includes surgery, radiation, endocrine therapy (hormonal treatment), and, depending on risk, chemotherapy.

The decision about whether to add chemotherapy to endocrine therapy is the key clinical question for most of these patients. Women with clearly high-risk tumors, based on size, lymph node involvement, and grade, typically receive chemotherapy. Women with clearly low-risk disease typically receive endocrine therapy alone. But a substantial middle group sits in ambiguous territory, where the right answer is not obvious from standard pathological features alone. This is precisely the population ArteraAI Breast is designed to help.

How ArteraAI Breast Works

The tool uses multimodal artificial intelligence (MMAI), a term that describes AI systems that combine multiple types of data rather than analyzing a single input. In this case, the two inputs are a digitized histopathology image and patient clinical variables.

The pathology slide input

When a breast tumor is surgically removed, tissue samples are processed, embedded in paraffin wax, sliced very thin, stained with standard dyes (hematoxylin and eosin, or H&E), and placed on glass slides. A pathologist reviews these slides under a microscope to assess tumor grade, cell type, and other features. For ArteraAI Breast, the same slides are digitally scanned at high resolution, creating whole-slide images that the AI analyzes. No additional staining, no additional tissue processing, and no additional cost for sample preparation.

The clinical variables input

Alongside the digitized image, the system incorporates standard patient clinical data such as age, tumor size, nodal status, and grade. This multimodal approach allows the AI to recognize patterns across both the visual features of the tumor tissue and the clinical context, producing a composite risk score that neither input alone could generate as accurately.

The output

ArteraAI Breast generates a numerical risk score that provides prognostic information on the likelihood of distant metastasis. Using a predefined risk score cutoff, patients are stratified into low-risk and high-risk groups. Artera reports that results are available within one to two days of receiving the digitized sample, and the test produces no inconclusive results based on insufficient tissue, which is a meaningful practical advantage over some existing molecular assays.

How does this differ from Oncotype DX and MammaPrint? Oncotype DX (Genomic Health/Exact Sciences) and MammaPrint (Agendia) are the two most widely used molecular risk stratification tests for early-stage HR+/HER2- breast cancer. Both analyze gene expression patterns in tumor tissue and generate recurrence risk scores. Both are validated in large clinical trials (TAILORx for Oncotype DX, MINDACT for MammaPrint) and incorporated into NCCN and ASCO guidelines. The key practical differences with ArteraAI Breast are the input type and the infrastructure required. Oncotype DX and MammaPrint require tumor tissue to be processed with specialized molecular assays, shipped to central laboratories, and analyzed using RNA extraction and gene expression profiling. This adds cost, processing time, and requires specific tissue handling. ArteraAI Breast uses the standard H&E pathology slides that every pathology laboratory already produces as part of routine diagnosis, digitized on equipment increasingly common in pathology labs. ArteraAI Breast does not yet have the decades of clinical validation data behind Oncotype DX and MammaPrint. The tools serve complementary rather than competing roles in the current clinical framework. As the evidence base for ArteraAI grows, the field will develop clearer guidance on how these tools should be used together or sequentially.

The Clinical Trial Data Behind the Clearance

The FDA clearance is supported by data from two clinical trials, both presented at the 2025 San Antonio Breast Cancer Symposium (SABCS).

ABCSG 8 trial: postmenopausal patients, 10-year outcomes

In a presentation evaluating postmenopausal patients from the ABCSG 8 trial (NCT00291759), the MMAI platform stratified patients into three risk groups with the following 10-year distant metastasis-free survival rates:

Risk group	10-year DMFS	Clinical meaning
Low risk	Approximately 95%	Very low likelihood of cancer spreading to distant organs within 10 years
Intermediate risk	Approximately 89%	Moderate likelihood; additional therapy discussion warranted
High risk	Approximately 77%	Substantially elevated risk; chemotherapy benefit more likely to outweigh harm

NSABP B-20 trial: chemotherapy benefit in high-risk patients

A separate presentation evaluated patients with node-negative, HR-positive disease from the NSABP B-20 trial. In the subset of patients the MMAI tool classified as high-risk, chemotherapy produced a 52% relative decrease in 10-year distant metastasis rates compared with no chemotherapy. This is the predictive component of the tool: not just identifying who has high recurrence risk, but identifying who actually benefits from adding chemotherapy.

The 52% figure is clinically significant. It suggests the AI is not merely sorting patients by overall risk level but identifying the biologically distinct group for whom chemotherapy’s mechanism of action provides substantial additional protection beyond endocrine therapy alone.

Both datasets were presented at SABCS 2025 rather than published in a peer-reviewed journal at the time of FDA clearance. Peer-reviewed publication of the full analyses will be an important milestone for establishing this tool’s position in clinical guidelines.

“Patients and clinicians need to understand their risks for recurrence and decide which treatments will be the most effective, thereby avoiding both undertreatment and overtreatment.” — Calvin Chao, MD, Vice President of Medical Science, Artera. Medical News Today, May 2026.

The Bigger Picture: AI Is Changing How Oncologists Make Treatment Decisions

ArteraAI Breast is part of a broader pattern in oncology: artificial intelligence tools are moving from research into regulated clinical practice, with specific cleared or approved uses that change how clinicians gather and act on diagnostic information. The FDA clearance for ArteraAI Breast came in the same month as several other landmark AI decisions in women’s health, reflecting a maturation of the regulatory pathway for these tools.

The clinical and societal significance of AI in this specific context is worth stating plainly. Approximately 300,000 women are diagnosed with breast cancer in the United States each year. A substantial fraction have early-stage HR+/HER2- disease, the exact population for whom the chemotherapy decision is genuinely uncertain. Any tool that reliably identifies the women who can safely avoid chemotherapy reduces harm at scale, not just for individual patients.

The challenge the field now faces is integration. Hospitals need digital pathology scanning infrastructure. Clinicians need to understand what the score means and how to incorporate it alongside existing tools. Guidelines from NCCN, ASCO, and other bodies will need to address how ArteraAI fits alongside Oncotype DX and MammaPrint in clinical decision-making. None of this happens automatically after FDA clearance.

What Patients with Early-Stage HR+/HER2- Breast Cancer Should Know

Is this tool available at my hospital?

ArteraAI Breast received FDA clearance on May 6, 2026. Commercial availability is being rolled out now. Not every hospital or pathology laboratory will have access immediately. Availability depends on whether the institution has digital pathology scanning capability and whether they have contracted with Artera. It is reasonable to ask your oncologist or breast surgeon whether their center uses ArteraAI or a similar digital pathology tool.

Does this replace Oncotype DX or other genomic tests?

Not currently. Oncotype DX and MammaPrint have more extensive published evidence and are incorporated into major clinical guidelines. ArteraAI Breast is a new cleared tool with promising validation data. The two types of tests are based on different biological signals and may provide complementary information. Your oncologist will determine which risk stratification approach is most appropriate for your specific situation.

What does a low-risk result mean in practice?

A low-risk score from ArteraAI Breast indicates that the tumor’s pathological features and your clinical characteristics, as analyzed by the AI, suggest a low probability of distant metastasis. It does not guarantee that cancer will not return. What it does provide is additional evidence that can inform the conversation with your oncologist about whether chemotherapy is likely to offer you a meaningful benefit. That conversation still requires individual clinical judgment, not just a test result.

What limitations exist?

The supporting data was presented at a conference, not yet published in a peer-reviewed journal. Peer-reviewed publication with full methodology and statistical detail is the standard against which tools are evaluated by guidelines committees. This is expected to follow, and the FDA clearance was granted on the basis of this data, but it is a relevant caveat.
The tool stratifies into low and high risk, not a single continuous recurrence score. Some other tools provide a continuous score with a range of risk thresholds. The binary or three-tier stratification provides clear decision support but may not capture the full spectrum of risk for every individual patient.
Long-term prospective data specifically tracking ArteraAI-guided treatment decisions and their outcomes does not yet exist. The existing validation uses retrospective data from prior trials. Prospective evidence that patients guided by ArteraAI scores have better outcomes than those guided by standard assessment alone will take time to accumulate.

The bottom line

For a large number of women with early-stage HR+/HER2- breast cancer, chemotherapy is a treatment they could safely skip. Identifying those women reliably at diagnosis has always been the challenge. ArteraAI Breast is a new, FDA-cleared tool that uses the pathology slide already generated during standard cancer diagnosis to produce a risk score within one to two days, with no additional tissue processing required. The clinical trial data supporting the clearance is promising, particularly the 52% reduction in distant metastasis with chemotherapy in the tool’s high-risk group. The limitations around peer-reviewed publication and prospective outcome data are real and worth tracking. For patients currently navigating a breast cancer diagnosis, the most useful next step is a conversation with a breast oncologist about which risk stratification tools are appropriate for your specific tumor and clinical profile. The National Cancer Institute Cancer Center directory and the Susan G. Komen helpline are strong starting points for connecting with specialized breast oncology care.

Sources

Artera FDA clearance press release: Artera Receives U.S. FDA Clearance for ArteraAI Breast, Expanding Its AI Platform to Breast Cancer. May 6, 2026.

CancerNetwork: FDA Clears AI Stratification Tool in HR+/HER2- Invasive Breast Cancer. CancerNetwork. May 2026.

ITN Online: FDA Clears AI Digital Pathology Risk Stratification Tool in Breast Cancer. Imaging Technology News. May 6, 2026.

Femtech Insider: Artera Receives FDA Clearance for AI-Powered Breast Cancer Risk Stratification Tool. Femtech Insider. 2026.

Medical News Today: FDA-cleared AI risk tool could help guide breast cancer therapy. Medical News Today. May 2026.

Medical Device Network: Artera hits US first with pathology-based breast cancer risk tool’s clearance. May 2026.

BusinessWire: Artera Receives U.S. FDA Clearance for ArteraAI Breast. BusinessWire. May 6, 2026.

LabMedica: FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification. LabMedica. 2026.

ABCSG 8 trial: Austrian Breast and Colorectal Cancer Study Group Trial 8 (NCT00291759).

NSABP B-20 trial: National Surgical Adjuvant Breast and Bowel Project B-20. ClinicalTrials.gov.

HED internal post (MASAI): AI-Supported Mammography Just Got Its Strongest Evidence Yet. Health Evidence Digest.

Disclaimer: Health Evidence Digest provides general information about FDA clearances and health research for educational purposes. This content is not a substitute for professional medical advice. ArteraAI Breast is a risk stratification aid and is not intended to replace clinical judgment. All treatment decisions for breast cancer should be made in consultation with a qualified oncologist.

May 13, 2026

AI-Supported Mammography Just Got Its Strongest Evidence Yet. Here Is What the Landmark MASAI Trial Found.

📌 The essentials The MASAI (Mammography Screening with Artificial Intelligence) trial, published in The Lancet on January 31, 2026, is the largest randomized controlled trial of AI in any cancer screening program ever conducted. In 105,934 women across Sweden, AI-supported mammography improved screening sensitivity from 73.8% to 80.5% (p=0.031) while specificity remained identical at 98.5% in both groups (p=0.88). The interval cancer rate, the gold standard measure of missed cancers between screenings, was lower in the AI group: 1.55 versus 1.76 per 1,000 women screened. AI reduced aggressive and advanced interval cancers specifically, including fewer non-luminal A (more aggressive) tumors in the AI group (43 versus 59). And AI triaged 44% of scans to single-reader review without loss of accuracy, directly addressing radiologist workforce constraints. This post covers what the trial measured, how the AI worked, what the numbers mean in practice, and what remains open.

Every year in the United States, roughly 40 million mammograms are performed. Each one is read by at least one radiologist, and in many countries including Sweden, by two. Reading is time-consuming, cognitively demanding, and subject to the same variation in judgment that affects every human visual task. Radiologists miss some cancers. They also flag some findings as suspicious that turn out to be benign, sending women back for additional imaging or biopsies they did not need.

The promise of artificial intelligence in mammography is that it could do better on at least one of those problems without making the other worse. Catch more cancers while generating no more unnecessary callbacks. Or reduce the reading burden on an overstretched radiologist workforce while maintaining safety. Ideally, both.

The MASAI trial, published in The Lancet on January 31, 2026, is the first and largest randomized controlled trial of AI in any cancer screening program. It enrolled over 105,000 women in Sweden and ran from April 2021 to December 2022. The full results answer the central questions directly: AI-supported mammography caught more cancers and produced no increase in false positives.

The Measure That Matters Most: What Is an Interval Cancer?

Before getting into the numbers, it helps to understand what the MASAI trial was primarily designed to measure. The primary endpoint was not detection rate during screening. It was the interval cancer rate.

An interval cancer is a breast cancer diagnosed between scheduled screening rounds, meaning after a mammogram that came back negative. These are the cancers the screening missed. A woman left the screening appointment with a clean bill of health and developed a symptomatic cancer before her next scheduled appointment. Interval cancers tend to be more aggressive than screen-detected cancers because aggressive tumors grow faster and are more likely to become apparent between screening rounds rather than at the next scheduled scan.

Reducing the interval cancer rate is the gold standard test of whether a screening program improvement is real. It means the test is catching more of the dangerous cancers before they become symptomatic, not just generating more detections of indolent findings that would never have harmed the patient.

The MASAI Trial: Design and What AI Was Actually Doing

The MASAI (Mammography Screening with Artificial Intelligence) trial (NCT04666026) was a randomized, controlled, single-blinded, population-based screening accuracy trial conducted across three regions in Sweden. Enrollment ran from April 2021 through December 2022. A total of 105,934 women were randomly assigned, with 105,915 eligible for the final analysis: 53,043 in the AI-supported group and 52,872 in the standard double-reading group.

The median age in both groups was approximately 54 years, consistent with a population-based screening program. Sweden screens eligible women every 1.5 to 2 years, or annually for those at higher risk.

How the AI worked in this trial

The AI system played two roles in the intervention arm. First, it triaged each mammogram scan for single or double reading by radiologists. Scans the AI assessed as lower risk were forwarded to a single radiologist read rather than the standard two-reader process. Scans assessed as higher risk received double reading with AI detection support. Second, in double-read cases, the AI highlighted suspicious areas on the images to assist the radiologists reviewing the scan.

The AI system used in MASAI was trained, validated, and tested on over 200,000 mammography scans before deployment. The control arm received standard double reading by two radiologists without any AI involvement.

The Results: What the Trial Found

Outcome	AI-supported	Standard double-read
Sensitivity	80.5% (95% CI 76.4 to 84.2%)	73.8% (95% CI 68.9 to 78.3%)
p-value for sensitivity	p=0.031	Reference
Specificity	98.5% (95% CI 98.4 to 98.6%)	98.5% (95% CI 98.4 to 98.6%)
p-value for specificity	p=0.88 (no difference)	Reference
Interval cancer rate (per 1,000)	1.55 (95% CI 1.23 to 1.92)	1.76 (95% CI 1.42 to 2.15)
Invasive interval cancers	75	89
T2+ stage interval cancers	38	48
Non-luminal A interval cancers	43	59
Reduction in radiologist workload	44% of scans routed to single-read	All scans double-read

Source: Gommers J et al. The Lancet. 2026;407(10527):505-514. doi:10.1016/S0140-6736(25)02464-X. PubMed PMID: 41620232.

The specificity finding is the critical reassurance

Sensitivity is the ability to detect cancer when it is present. Specificity is the ability to correctly clear patients who do not have cancer. The two are often in tension: systems designed to catch more cancers tend to generate more false alarms. The MASAI finding that specificity was identical at 98.5% in both groups (p=0.88) is therefore one of the most important numbers in the entire dataset. AI caught more cancers without generating more unnecessary callbacks or biopsies. That is the combination the field has been working toward.

What the interval cancer characteristics tell us

The numbers behind the 12% reduction in interval cancers are worth examining carefully. Women in the AI-supported group had fewer interval cancers that were invasive (75 versus 89), fewer that had reached T2 or larger size (38 versus 48), and fewer that were non-luminal A subtype (43 versus 59). Non-luminal A tumors are the more aggressive breast cancer subtypes, including triple-negative and HER2-positive cancers. Their reduction is particularly meaningful because these are the cancers where early detection makes the biggest difference to survival.

The lead author of the MASAI trial, Dr. Kristina Lang of Lund University’s Division of Diagnostic Radiology, noted in the published report that the trial found AI-supported screening improves the early detection of clinically relevant breast cancers, reducing aggressive and advanced cancers diagnosed in between screenings. She also noted at the time of publication that AI adoption must be done carefully, with tested tools and continuous monitoring.

A Second 2026 Study in Nature Cancer: AI Increased Detection From 7.54 to 9.33 Per 1,000 Women

The MASAI results are part of a broader pattern of evidence building in 2026. A separate study published in Nature Cancer reported that AI-supported mammography increased cancer detection from 7.54 to 9.33 per 1,000 women screened. That translates to roughly 1.8 additional cancers detected per 1,000 women in a given screening round, or about 1 in 556 women screened gaining a detection they would have missed under standard reading.

The two studies use different endpoints and populations, so direct numerical comparison is limited. Together, they strengthen the evidence that AI-supported mammography reading improves cancer yield in real-world screening settings, not just in retrospective analyses of selected image archives.

What This Means for Patients Who Get Mammograms Today

Is AI reading my mammogram now?

Possibly. Several FDA-cleared AI systems for mammography assistance are in use at imaging centers and hospitals across the United States, including Transpara (ScreenPoint Medical) and iCAD. The specific AI tool used in the MASAI trial is not the only one commercially available, and the evidence base for individual products varies. The MASAI trial result tells us that when a well-validated AI system is integrated into a structured screening workflow, the combined result outperforms standard double reading. It does not automatically apply to every AI product on every platform.

Does AI replace the radiologist?

No. In the MASAI trial design, AI triaged scans to single or double reading by radiologists and highlighted suspicious areas for radiologist review. A radiologist made every final read. The AI reduced how many scans required two radiologists’ time and provided detection support to the reader who reviewed each case. The result was a 44% reduction in the portion of radiologist reading time devoted to double reads, without loss of accuracy.

This matters for healthcare systems facing radiologist workforce shortages. The United States and many European countries have a well-documented shortage of breast imaging specialists. A technology that allows the same number of radiologists to safely read more scans without reducing quality addresses a real structural problem in cancer screening infrastructure.

Will AI increase false alarms?

The MASAI trial specifically answers this. Specificity was 98.5% in both groups and the difference was not statistically significant (p=0.88). This is a reassurance, not a trivial finding. An AI system that drove up the recall rate would expose women to unnecessary imaging anxiety and follow-up procedures. Maintaining specificity while improving sensitivity is the combination that makes AI integration clinically viable rather than just mathematically impressive.

What interval cancers found in the study tell us about AI and aggressive tumors The 12% reduction in interval cancers in the AI arm is the most clinically meaningful finding for patients who actually get mammograms. Interval cancers are the ones that grow between screenings and become symptomatic before the next scheduled appointment. They tend to be more aggressive precisely because aggressive tumors grow faster. The MASAI data specifically showed the AI arm had fewer T2-or-larger interval cancers (38 versus 48) and fewer non-luminal A tumors (43 versus 59). Non-luminal A cancers are the harder-to-treat subtypes, including triple-negative and HER2-positive disease. Reducing the interval rate for these subtypes, not just for all cancers in aggregate, is what the trial’s authors describe as clinically relevant improvement. The benefit of higher sensitivity was consistent across age groups and breast density categories. Women with dense breast tissue, who are often told that mammography is less reliable for them, saw the same relative benefit from AI support as women with non-dense tissue.

What the Study Does Not Tell Us

The MASAI results are strong and the trial design is rigorous. Honest presentation of the evidence also requires naming what remains open.

This trial used one specific AI system. The results apply to the validated tool used in MASAI. There are multiple AI mammography products on the market with varying levels of clinical evidence behind them. FDA clearance for a device does not automatically mean its performance matches the MASAI AI system in this structured workflow.

Long-term survival data is not yet reported. The trial measured interval cancer rates and tumor characteristics, not survival outcomes. Whether the improved early detection translates into reduced breast cancer mortality over 10 to 20 years is the most important unanswered question. Based on what we know about how interval cancer rates relate to mortality in breast screening, the expectation is that it does, but long-term data from this cohort will be needed to confirm.

The trial was conducted in Sweden. Sweden has a national, population-based screening program with standardized protocols. Results may differ in healthcare systems with more fragmented screening delivery, different population characteristics, or different baseline double-reading rates.

Not all AI reads improve on human performance equally. A secondary analysis of the trial noted that the sensitivity improvement applied to invasive cancers but not to in-situ cancers specifically. Understanding which cancer types AI improves detection for, and which it does not, matters for interpreting the clinical impact.

Practical Guidance for People Due for a Mammogram

If you are due for a mammogram and have been putting it off, this study does not change the recommendation to screen. It strengthens it. Current American Cancer Society guidelines recommend annual mammograms starting at age 40 for average-risk women.

If your imaging center uses AI-assisted reading, it is reasonable to ask which system they use and whether it has been prospectively validated in clinical trials, not just retrospective analyses.

If you receive a callback for additional imaging after a mammogram, that is not necessarily a sign something went wrong. Recall rates remained the same under AI-supported reading in this trial. Most callbacks do not result in a cancer diagnosis.

For women with dense breast tissue who have been told mammography is less sensitive for them: the MASAI data showed the AI benefit was consistent across breast density categories. That is an encouraging finding, though supplemental screening options remain a separate conversation to have with your provider.

Screening intervals have not changed based on this evidence. The MASAI results strengthen the case for regular mammography participation, not for altering how often you screen.

For related women’s health coverage on Health Evidence Digest, see our post on new 2026 cervical cancer screening guidelines that now allow self-collection for HPV testing, as well as our coverage of pembrolizumab becoming the first approved immunotherapy for ovarian cancer.

Sources

Primary publication: Gommers J, Hernstrom V, Josefsson V, et al. Interval cancer, sensitivity, and specificity comparing AI-supported mammography screening with standard double reading without AI in the MASAI study. The Lancet. 2026;407(10527):505-514. doi:10.1016/S0140-6736(25)02464-X. PubMed PMID: 41620232.

MASAI trial registration: NCT04666026. ClinicalTrials.gov.

ASCO Post coverage: Randomized Trial Shows AI-Supported Mammography Improves Sensitivity and Lowers Interval Cancer Rate. The ASCO Post. February 2, 2026.

EurekAlert/Lancet press release: AI-supported mammography screening results in fewer aggressive and advanced breast cancers, finds full results from first randomized controlled trial. EurekAlert. January 29, 2026.

AJMC coverage: AI-Supported Mammography Caught More Cancers During Screening. AJMC. 2026.

Lund University press release: AI support in breast cancer screening: Fewer missed cancer cases. Lund University. January 30, 2026.

MASAI interim safety results (2023): Lång K et al. Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study. The Lancet Oncology. 2023;24(8):936-944.

MASAI AI detection analysis (2024): Lång K et al. Identifying normal mammograms in a large screening population using artificial intelligence. Lancet Digital Health. 2024. doi:10.1016/S2589-7500(24)00267-X

Patient resources: American Cancer Society mammography guidelines | National Cancer Institute | Dense Breast Info

Disclaimer: Health Evidence Digest provides general information about health research for educational purposes. This content does not constitute medical advice and is not a substitute for consultation with a qualified healthcare provider. Mammography screening recommendations should be discussed with your physician based on your individual health history and risk factors.

Disclaimer: Health Evidence Digest provides general information about health research for educational purposes. This content does not constitute medical advice and is not a substitute for consultation with a qualified healthcare provider. Mammography screening recommendations should be discussed with your physician based on your individual health history and risk factors.

May 12, 2026

The FDA Said Yes to One ESR1 Drug and No to Another. What That Tells Us About the Future of Targeted Breast Cancer Treatment.

📌 The essentials On April 30, 2026, the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 6 to 3 against the clinical benefit of switching to camizestrant (AstraZeneca) in patients with HR-positive, HER2-negative metastatic breast cancer upon detection of an emerging ESR1 mutation during first-line therapy, before radiographic disease progression. The vote was based on data from the SERENA-6 Phase 3 trial. One day later, on May 1, 2026, the FDA approved vepdegestrant (Veppanu, Arvinas/Pfizer) for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after prior endocrine therapy. Both decisions involve ESR1 mutations in the same general patient population. They reached opposite conclusions. This post explains why, and what the difference reveals about how the FDA evaluates evidence in precision oncology.

Within 24 hours in late April and early May 2026, the FDA’s approach to ESR1-guided breast cancer treatment produced two very different outcomes. On the same day that an advisory panel voted against approving camizestrant for a ctDNA-guided treatment switch before disease progression, vepdegestrant was on its way to full FDA approval for the same patient population at a later stage of treatment. Understanding why these two decisions went in opposite directions requires understanding exactly what each drug was asking the FDA to accept.

What ESR1 Mutations Are and Why They Matter

ESR1 mutations occur in the gene that encodes the estrogen receptor. In patients with hormone receptor-positive, HER2-negative breast cancer, the estrogen receptor is the primary driver of tumor growth, which is why endocrine therapies that block or degrade it form the backbone of treatment.

The problem is that treatment pressure on the estrogen receptor eventually selects for mutations that allow it to remain active even in the absence of estrogen. These ESR1 mutations are acquired, meaning they typically arise during treatment rather than being present at diagnosis. They are detected in approximately 40 to 50% of patients who progress on first-line endocrine therapy plus a CDK4/6 inhibitor. When they emerge, they signal developing resistance and predict poor outcomes on continued aromatase inhibitor-based therapy.

Liquid biopsy technology, specifically circulating tumor DNA (ctDNA) testing, can now detect these mutations from a blood draw, often before the tumor shows measurable growth on a scan. That capability is central to both of the regulatory stories described in this post, but in two very different ways.

Vepdegestrant: The Approval That Happened

On May 1, 2026, the FDA approved vepdegestrant (Veppanu) for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer who had disease progression following at least one line of endocrine therapy. The approval arrived more than a month ahead of the June 5 PDUFA date, a signal that the FDA’s review was straightforward.

The approval simultaneously authorized the Guardant360 CDx liquid biopsy as a companion diagnostic to identify patients with ESR1 mutations who are eligible for treatment.

What the VERITAC-2 Trial Showed

The approval was based on data from VERITAC-2 (NCT05654623), a global, randomized, open-label Phase 3 trial that enrolled 624 patients at 213 sites across 25 countries. Patients were required to have disease progression on one to two lines of endocrine therapy, including one line with a CDK4/6 inhibitor. They were randomized 1:1 to receive either vepdegestrant orally once daily or fulvestrant intramuscularly.

In the 270-patient ESR1-mutated subgroup that drove the approval, vepdegestrant reduced the risk of disease progression or death by 43% compared to fulvestrant, with a median progression-free survival of 5.0 months versus 2.1 months (hazard ratio 0.57; 95% CI 0.42 to 0.77; p=0.0001). Across the overall trial population, regardless of ESR1 status, the PFS benefit did not reach statistical significance (hazard ratio 0.83; p=0.07), which reinforces the importance of ESR1 mutation testing before treatment selection and underscores that this approval is strictly for the ESR1-mutated population. Overall survival data are still immature, with only 16% of deaths having occurred at the time of the PFS analysis.

The VERITAC-2 results were presented at the 2025 ASCO Annual Meeting and simultaneously published in The New England Journal of Medicine.

What Makes Vepdegestrant Mechanistically Different

Vepdegestrant is more than a new drug in an existing class. It is the first PROTAC (proteolysis-targeting chimera) to receive FDA approval for any indication, making this a landmark regulatory event beyond its breast cancer-specific context.

Traditional SERDs (selective estrogen receptor degraders) like fulvestrant and elacestrant work by binding the estrogen receptor and triggering its degradation. Vepdegestrant takes a different approach: it is a bifunctional molecule that simultaneously recruits the estrogen receptor on one end and a cellular protein-degradation machinery component called an E3 ubiquitin ligase on the other. By bringing these two proteins into proximity, it directs the cell’s own waste-disposal system to destroy the estrogen receptor completely rather than simply blocking it.

This catalytic mechanism means one molecule of vepdegestrant can degrade multiple copies of the estrogen receptor and is then recycled to degrade more. It eliminates the receptor rather than occupying it, which is mechanistically important when dealing with ESR1 mutations that cause the receptor to remain active even when blocked.

We covered the full PROTAC mechanism and the VERITAC-2 trial data in detail here. The May 1 FDA approval means that post is now confirmed, and the drug is commercially available.

What Patients Should Know About Vepdegestrant

Vepdegestrant (Veppanu) is an oral once-daily tablet taken with food at a dose of 200 mg. It is indicated for patients who have already progressed on at least one line of endocrine therapy, including a CDK4/6 inhibitor. ESR1 mutation testing with an FDA-authorized ctDNA assay such as Guardant360 CDx is required before starting treatment.

The FDA label includes warnings about QTc interval prolongation (a heart rhythm consideration that requires monitoring) and embryo-fetal toxicity. The most common adverse effects across the trial were musculoskeletal pain, nausea, fatigue, hot flashes, and headache. Patients should discuss the full safety profile with their oncologist.

Camizestrant: The Vote Against

The ODAC vote on April 30, 2026, addressed a very different question. AstraZeneca was not asking the FDA to approve camizestrant for patients who had already progressed. It was asking whether camizestrant should be approved for patients who had developed an ESR1 mutation in a ctDNA blood test but had not yet shown radiographic evidence of disease progression on their current treatment.

This is a fundamentally different clinical scenario, and the distinction is the reason the vote went against approval.

The SERENA-6 Trial Design

SERENA-6 (NCT04964934) enrolled patients with HR-positive, HER2-negative advanced breast cancer who were stable on first-line aromatase inhibitor plus CDK4/6 inhibitor therapy for at least six months. Every two to three months, patients had ctDNA testing using the Guardant360 CDx assay. When an ESR1 mutation was detected in the blood, patients who had no evidence of disease progression on imaging were randomized to either continue their existing therapy or switch to camizestrant 75 mg plus their CDK4/6 inhibitor.

The PFS results were numerically compelling. The median PFS was 16.0 months in the camizestrant arm versus 9.2 months in the continued-aromatase-inhibitor arm (hazard ratio 0.44; p less than 0.00001). By the conventional statistical measures, this looks like a large effect. The ODAC voted 6 to 3 against it anyway. Why?

Why ODAC Said No

The committee’s concerns centered on three interconnected problems with interpreting the trial’s results as evidence of clinically meaningful benefit.

The PFS time zero problem. In SERENA-6, progression-free survival was measured from the time of randomization, which occurred at ESR1 mutation detection rather than at the start of treatment. Patients in the control arm who were still on therapy at randomization were inevitably closer to their next progression event than patients who had just started a new drug. This creates a structural asymmetry in how PFS is measured across the two arms that is not a drug effect. FDA reviewers flagged this as a nonstandard PFS time zero that complicates interpretation.

PFS2 is confounded by the protocol design. PFS2 (time to progression on the next line of therapy) is sometimes used as a supporting endpoint to demonstrate that a PFS benefit translates downstream. In SERENA-6, patients in the control arm were switched to camizestrant upon progression, as specified in the protocol. This protocol-mandated switch means PFS2 cannot serve as an independent confirmation of benefit, because both arms ultimately received the same drug.

Overall survival is immature and uncertain. OS data at the time of the ODAC meeting were too early to be interpretable. Committee members noted that without a mature OS signal, and with the PFS data carrying the methodological concerns described above, there was insufficient evidence that the ctDNA-guided switch before progression meaningfully improved patient outcomes compared to simply switching at the time of standard radiographic progression.

One additional safety note that ODAC discussed: there is a signal of potential cardiac toxicity when camizestrant is combined with ribociclib, one of the CDK4/6 inhibitors used in the trial. This was not a primary reason for the negative vote, but it added to the committee’s caution.

The Conceptual Question at the Heart of Both Decisions

Camizestrant and vepdegestrant both target ESR1 mutations. Both are oral SERDs (camizestrant) or SERD-class agents (vepdegestrant). But they were asking the FDA to accept fundamentally different propositions.

Vepdegestrant asked: does this drug help patients after they have already progressed on prior therapy? This is a well-established clinical endpoint with clear time zero, an appropriate comparator (fulvestrant, which is the current standard), and a patient population that has a demonstrated unmet need. The answer was yes.

Camizestrant asked: should treatment be switched based on a molecular signal in the blood, before the patient shows any clinical or radiographic signs of progression? This is a newer paradigm in precision oncology called ctDNA-guided adaptive therapy, and the SERENA-6 trial was the first global registrational trial to test it. The FDA’s position, reflected in the ODAC vote, was that SERENA-6 did not adequately answer this question.

The comparison matters because it illustrates a distinction that runs through many recent oncology regulatory debates. A large PFS hazard ratio is not by itself sufficient evidence of clinical benefit if the design creates ambiguity about what is actually being measured. ODAC members were not questioning whether camizestrant is an active drug. Several acknowledged that the drug likely has meaningful anti-tumor activity. What they were questioning is whether the SERENA-6 trial design adequately demonstrated that switching before progression is better for patients than switching at progression, which is the standard approach.

What Happens to Camizestrant Next

An ODAC vote against clinical benefit does not automatically result in a formal FDA rejection, but it is a strong signal. Given that the FDA’s own reviewers raised similar concerns before the advisory committee meeting, approval of the specific indication tested in SERENA-6 is unlikely without additional data.

AstraZeneca has separate ongoing trials for camizestrant in different settings. The SERENA-4 trial is evaluating camizestrant in the first-line setting for HR-positive, HER2-negative advanced breast cancer, which is a different clinical question and regulatory submission. A negative ODAC vote on one trial in one specific indication does not preclude a different regulatory outcome for the same drug in a different setting.

What ctDNA-Guided Treatment Really Means for the Field

SERENA-6 was the first randomized registrational trial to test the concept of using a liquid biopsy molecular signal to guide a treatment switch before clinical progression. The ODAC vote does not close the door on this concept. It identifies what the evidence will need to look like for regulators to accept it.

The fundamental question is whether catching and responding to molecular resistance earlier than radiographic progression meaningfully changes patient outcomes. The biological rationale is plausible: treating a smaller, less heterogeneous tumor burden before the clone driving resistance has fully taken over should theoretically be advantageous. But biological plausibility and clinical proof are different things. The trial design challenges in SERENA-6 made it difficult for the committee to separate the drug’s effect from the structural features of the ctDNA-guided randomization approach.

Future trials in this space will likely need to address the PFS time zero issue directly, use OS or PFS2 endpoints that are not confounded by protocol-mandated switches, and potentially show head-to-head evidence that pre-progression switching outperforms standard progression-triggered switching. That is a harder evidentiary bar, but it is a consistent one. The FDA has applied similar rigor to other adaptive precision oncology designs.

For patients with HR-positive metastatic breast cancer and their oncologists, the practical takeaway is that ctDNA testing for ESR1 mutations is increasingly central to treatment decisions. The Guardant360 CDx approval as a companion diagnostic for vepdegestrant means ESR1 liquid biopsy testing is now both clinically actionable and reimbursement-supported in the context of that approved indication. Whether it will also be used to guide pre-progression switches remains an open question pending further evidence.

What to Ask Your Oncologist

If you have HR-positive, HER2-negative advanced or metastatic breast cancer and have progressed on prior endocrine therapy including a CDK4/6 inhibitor, ask whether ESR1 mutation testing has been done on a recent blood sample. If an ESR1 mutation is present, vepdegestrant (Veppanu) is now an approved option and should be part of the treatment discussion.

If you are currently stable on first-line aromatase inhibitor plus CDK4/6 inhibitor therapy, the ctDNA-guided pre-progression switch with camizestrant is not currently an approved approach based on the April 30 ODAC vote. Routine ESR1 monitoring during first-line therapy is likely to be discussed by your oncologist as evidence continues to develop, but it should not change your current treatment plan without a direct conversation with your care team.

For information on clinical trials evaluating newer approaches to ESR1-mutated breast cancer, ClinicalTrials.gov is the primary reference.

Sources

FDA approval of vepdegestrant: FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. FDA.gov. May 1, 2026.

VERITAC-2 trial registration: NCT05654623. ClinicalTrials.gov.

Arvinas FDA approval announcement: Arvinas Announces FDA Approval of VEPPANU (vepdegestrant). GlobeNewswire. May 1, 2026.

Targeted Oncology vepdegestrant approval: FDA Approves Vepdegestrant for ESR1-Mutated ER+/HER2- Advanced Breast Cancer. Targeted Oncology. May 2026.

OncLive ODAC vote coverage: FDA ODAC Votes Against Clinical Benefit of Switching to Camizestrant in HR+ Breast Cancer After ESR1 Mutation Detection. OncLive. April 30, 2026.

CancerNetwork ODAC coverage: FDA ODAC Votes No to Camizestrant for HR+/HER2- ESR1 Advanced Breast Cancer. CancerNetwork. April 2026.

Targeted Oncology ODAC coverage: FDA’s ODAC Votes Against Camizestrant in Advanced Breast Cancer. Targeted Oncology. April 2026.

AstraZeneca press release on ODAC vote: Update on FDA Advisory Committee vote on camizestrant. AstraZeneca. April 30, 2026.

OncLive April breast cancer flashback: FDA Flashback: Breast Cancer Decisions and News From April 2026. OncLive. 2026.

SERENA-6 trial registration: NCT04964934. ClinicalTrials.gov.

ESR1 mutation background: ESR1 mutations in breast cancer. StatPearls. NCBI.

AACR Q1 2026 Approvals: FDA Approvals in Oncology: January-March 2026. AACR Cancer Research Catalyst. April 2026.

Disclaimer: Health Evidence Digest provides general information about FDA regulatory processes, clinical trial results, and oncology research for educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment. Vepdegestrant (Veppanu) is FDA-approved and commercially available; camizestrant is not approved in the indication discussed in this post. Treatment decisions for advanced breast cancer should be made in close consultation with a qualified oncologist who can evaluate your individual diagnosis, mutation status, and treatment history.

May 10, 2026

A New ADC Has Priority Review for the Hardest-to-Treat Breast Cancer Subtype. Here’s What the Phase 3 Data Shows.

📌 The essentials PDUFA date: Q2 2026. The FDA is expected to rule on datopotamab deruxtecan (Dato-DXd, brand name Datroway), developed by AstraZeneca and Daiichi Sankyo, for first-line treatment of metastatic triple-negative breast cancer in patients ineligible for immunotherapy. The clinical case: In the TROPION-Breast02 Phase 3 trial, Dato-DXd extended median progression-free survival from 5.6 months to 10.8 months and overall survival from 18.7 months to 23.7 months versus chemotherapy. Both primary endpoints reached statistical significance. What makes it significant: If approved, Dato-DXd would be the first non-chemotherapy, non-immunotherapy first-line option for this specific population. This post covers the biology of TNBC, who is immunotherapy-ineligible and why, the full TROPION-Breast02 data including important context, the safety profile, and what approval would mean for patients navigating this diagnosis.

Triple-negative breast cancer is defined by what it lacks: no estrogen receptor, no progesterone receptor, no HER2 amplification. Those absences mean that the targeted therapies which have transformed outcomes in other breast cancer subtypes do not apply here. For decades, chemotherapy was the only systemic option. Then, in 2020, immunotherapy arrived for patients whose tumors expressed the PD-L1 protein. A meaningful advance for those patients. But not everyone qualifies.

Patients with metastatic TNBC who are ineligible for immunotherapy have historically had the fewest options and the worst outcomes of any breast cancer population. Their first-line treatment has remained standard cytotoxic chemotherapy, with all the toxicity that entails and a median overall survival below two years.

Datopotamab deruxtecan (Dato-DXd, brand name Datroway) is now seeking to change that. Developed by AstraZeneca and Daiichi Sankyo, the drug already received FDA approval in January 2025 for a different breast cancer subtype (HR-positive, HER2-negative). Now it has Priority Review for a new indication: first-line treatment of metastatic TNBC in patients who are not candidates for immunotherapy. The PDUFA date falls in Q2 2026. The Phase 3 TROPION-Breast02 trial, published in the Annals of Oncology in April 2026, produced results that oncologists are calling a potential new standard of care.

Triple-Negative Breast Cancer: The Biology, the Burden, and the Disparities

Triple-negative breast cancer accounts for approximately 15% of all breast cancer diagnoses in the United States, roughly 35,000 new cases per year. Despite representing a minority of breast cancer cases, it accounts for a disproportionate share of breast cancer deaths because of its aggressive biology, its relative resistance to treatment, and its tendency to be diagnosed at younger ages and at more advanced stages.

The racial disparities in TNBC are well documented and clinically significant. Black women are diagnosed with TNBC at roughly twice the rate of white women. They are more likely to be diagnosed at younger ages and more advanced stages. And despite these higher incidence rates, access to specialist oncology care and novel therapies has historically been unequal. Any advance in TNBC outcomes is therefore not just an oncologic milestone but a health equity issue.

Who is ineligible for immunotherapy in TNBC, and why this population matters Since 2020 and 2021, PD-L1 checkpoint inhibitors (atezolizumab and then pembrolizumab) have been approved as first-line options for metastatic TNBC. Pembrolizumab with chemotherapy is now the standard of care for PD-L1-positive metastatic TNBC, and it produces a meaningful survival benefit in that population. However, PD-L1 positivity is not universal in TNBC. Depending on the assay and scoring method used, approximately 40 to 60 percent of metastatic TNBC patients have PD-L1-positive tumors. The remainder, along with patients who cannot receive immunotherapy due to autoimmune disease, organ transplant status, or other contraindications, fall into the immunotherapy-ineligible category. TROPION-Breast02 enrolled specifically and exclusively these patients. This is the population for which first-line treatment has remained unchanged at standard chemotherapy for decades, and the population for which Dato-DXd is seeking approval.

What Is Dato-DXd and How Does It Work?

Datopotamab deruxtecan is an antibody-drug conjugate, part of the same drug class as trastuzumab deruxtecan (Enhertu/T-DXd) and sacituzumab govitecan (Trodelvy). All ADCs share the same general architecture: an antibody that recognizes a target protein on cancer cell surfaces, linked to a chemotherapy payload. The antibody finds the cancer cell, binds to it, is internalized, and releases the payload inside the cell.

Dato-DXd’s target is TROP2 (trophoblast cell-surface antigen 2), a protein expressed at high levels on the surface of many solid tumors, including the majority of TNBC tumors. The payload is DXd, a topoisomerase I inhibitor derived from exatecan. When the ADC is internalized into TROP2-expressing tumor cells, the linker is cleaved and DXd is released inside the cell, interfering with DNA replication and causing cancer cell death.

The linker technology is an important distinguishing feature. The cleavable tetrapeptide-based linker used in Dato-DXd is designed to be stable in the bloodstream but cleaved efficiently inside cells. This stability reduces off-target payload release in circulation, which contributes to a lower rate of hematologic toxicity compared to some earlier ADC platforms. The same DXd payload and linker technology is used in T-DXd (Enhertu), which explains the shared class safety signal of interstitial lung disease and stomatitis across both drugs.

Dato-DXd versus sacituzumab govitecan (Trodelvy): both target TROP2, but differently Sacituzumab govitecan (Trodelvy) is the other FDA-approved TROP2-directed ADC in breast cancer. It is approved for previously treated metastatic TNBC and for HR-positive HER2-negative metastatic breast cancer. Both it and Dato-DXd target TROP2, but they use different antibodies, different payloads (SN-38 for sacituzumab vs. DXd for datopotamab), and different linker technologies. The practical difference shows up in the safety profile: sacituzumab govitecan has higher rates of hematologic toxicity (neutropenia, diarrhea) while Dato-DXd’s signature toxicities are stomatitis and ocular surface events. Neither has been compared head-to-head in TNBC. They occupy different approved settings, and the question of how to sequence them in the metastatic TNBC treatment landscape is one the field will need to work out as approvals evolve. The panel discussion at OncLive noted that differences in linker technology and payload between the two drugs may influence clinical outcomes, but no definitive comparative data exists. Clinicians should be familiar with both safety profiles to counsel patients appropriately.

TROPION-Breast02: Design and Full Results

Trial design

TROPION-Breast02 (NCT05374512) was a randomized, open-label, international Phase 3 trial conducted across multiple countries. Between May 2022 and June 2024, 644 patients with previously untreated, locally recurrent inoperable or metastatic TNBC who were not candidates for PD-1/PD-L1 inhibitors were randomized 1:1 to Dato-DXd (6 mg/kg intravenously every 3 weeks, n=323) or investigator’s choice of chemotherapy (ICC, n=321). ICC options included paclitaxel, nab-paclitaxel, carboplatin, capecitabine, or eribulin mesylate. Randomization was stratified by geographic region, disease-free interval, and PD-L1 status.

The trial had dual primary endpoints: progression-free survival by blinded independent central review (BICR) per RECIST 1.1, and overall survival. Both primary endpoints were required to demonstrate statistical significance for the trial to be considered successful. Achieving both is a notable distinction in a disease setting where OS data is often immature at the time of initial analysis.

Efficacy results

Efficacy endpoint	Dato-DXd (n=323)	Chemotherapy (n=321)
Median PFS (BICR)	10.8 months (95% CI 8.6–13.0)	5.6 months (95% CI 5.0–7.0)
PFS hazard ratio	0.57 (95% CI 0.47–0.69; p<0.0001)	Reference
Risk reduction in progression/death	43%	Reference
12-month PFS rate	45.6%	25.6%
18-month PFS rate	32.7%	16.8%
Median OS	23.7 months	18.7 months
OS hazard ratio	0.79 (21% reduction in risk of death; p<0.05)	Reference
Median treatment duration	6.7 months	4.1 months
Patients on treatment at data cutoff	Longer than chemo arm	Shorter duration

Source: Dent RA et al. Annals of Oncology. 2026 Apr 3. doi:10.1016/j.annonc.2026.03.008. Presented at ESMO Congress 2025, Berlin (Abstract LBA21).

The PFS result is the most striking number: 10.8 versus 5.6 months is a near doubling of the time to disease progression or death. The 12-month PFS rates tell a related story: at one year, 45.6% of patients on Dato-DXd were progression-free, compared to 25.6% on chemotherapy. At 18 months, those rates were 32.7% versus 16.8%.

The OS result of 23.7 versus 18.7 months represents approximately five additional months of survival, with a statistically significant hazard ratio of 0.79. Having both PFS and OS meet statistical significance in the same trial is an important finding. Many oncology trials achieve PFS endpoints but fail to translate that into an OS benefit, sometimes because subsequent therapies after disease progression equalize outcomes across arms. TROPION-Breast02 demonstrated both.

The 6.7 versus 4.1 month median treatment duration favoring Dato-DXd is an indirect measure of tolerability: patients stayed on the experimental treatment longer, suggesting the drug was manageable enough to continue. That observation is supported by the safety data.

For patients with ER-positive disease, a separate PROTAC-based therapy is simultaneously under FDA review. Read about it here.

Safety: A Different Toxicity Profile Than Chemotherapy

Dato-DXd does not look like chemotherapy in its safety profile. Where chemotherapy predominantly causes hematologic toxicity (neutropenia, anemia, febrile neutropenia), Dato-DXd’s characteristic adverse effects are mucosal (stomatitis) and ocular. This difference matters for patient counseling and clinical management.

Safety metric	Dato-DXd	Chemotherapy (ICC)
Any treatment-related adverse event	93%	83%
Grade 3 or higher TRAEs	33%	29%
Serious treatment-related AEs	9%	8%
Discontinuation due to TRAEs	4%	7%
Treatment-related deaths	0	0
Stomatitis (all grade)	57%	Lower
Nausea (all grade)	45%	Lower
Alopecia (all grade)	41%	21%
Ocular surface events (grade 1, dry eye/keratitis)	24%	3%
ILD/pneumonitis (drug-related, adjudicated)	Less than 1%	Less than 1%
Hematologic toxicity (neutropenia, anemia)	Lower than chemo arm	Predominant toxicity

Several aspects of this safety data are worth emphasizing for clinical context. First, discontinuation due to treatment-related adverse events was actually lower with Dato-DXd (4%) than with chemotherapy (7%). This means patients on the experimental arm were less likely to stop treatment because of toxicity despite the higher overall rate of any adverse event. The profile is different, not simply worse.

Second, stomatitis at 57% is high in absolute terms but predominantly low-grade. The OncLive panel reviewing these results noted that proactive oral care management, including steroid-based mouthwash protocols (expanded from the SWISH trial experience with everolimus), can substantially reduce the incidence and severity of high-grade stomatitis. Institutions implementing Dato-DXd will need nursing education focused on stomatitis prevention and grading.

Third, ocular surface events (dry eye, keratitis) at 24% are almost entirely grade 1 and manageable with lubricating eye drops and ophthalmologic monitoring. The ILD rate of less than 1% is consistent with the known Dato-DXd class signal, lower than what is seen with T-DXd at current doses. ILD monitoring, prompt evaluation of respiratory symptoms, and early intervention with corticosteroids for confirmed cases remain important clinical requirements.

Context: How This Fits Into the TNBC Treatment Landscape

If approved, Dato-DXd would become the first non-chemotherapy, non-immunotherapy first-line option for metastatic TNBC patients who cannot receive checkpoint inhibitors. The treatment landscape for this population would shift in two meaningful ways.

First, the starting line for subsequent treatment sequencing changes. Patients who progress on first-line Dato-DXd will have had an ADC with a specific toxicity profile and resistance pattern. How sacituzumab govitecan (Trodelvy), currently approved in previously treated metastatic TNBC, performs after Dato-DXd progression is not established. This sequencing question will drive post-approval research.

Second, the ADC revolution in breast cancer treatment is now reaching the TNBC immunotherapy-ineligible population specifically. T-DXd reshaped HER2-positive and HER2-low metastatic breast cancer. Sacituzumab govitecan improved outcomes in previously treated TNBC. Dato-DXd, if approved, would extend ADC-based first-line treatment into a subgroup previously limited to cytotoxic chemotherapy.

What the TROPION-Breast01 trial (HR+/HER2- breast cancer) can teach us here Dato-DXd’s January 2025 FDA approval for HR-positive, HER2-negative metastatic breast cancer came from the TROPION-Breast01 trial. That trial met its primary PFS endpoint but did not achieve statistical significance on OS. The explanation offered by investigators was that subsequent ADC treatment in the control arm after disease progression may have equalized survival outcomes. TROPION-Breast02 in TNBC is different in a clinically important way: it achieved statistical significance on both PFS and OS. This distinction matters for the regulatory submission and for clinician confidence. When a trial achieves the survival endpoint and not just the surrogate, the benefit-risk assessment is on firmer ground. The difference in OS outcomes between the two trials also highlights how patient population and available subsequent therapies shape survival data. TNBC patients in TROPION-Breast02 had fewer subsequent treatment options after progression compared to HR+ patients, which may have allowed the OS benefit to emerge more clearly in this trial.

Dato-DXd (Datroway) is currently FDA-approved for HR-positive, HER2-negative breast cancer. The TNBC indication is under Priority Review with a PDUFA date in Q2 2026. Until a decision is issued, this drug is not available for TNBC outside of clinical trials. Priority Review means the FDA will aim to complete its review within 6 months of application acceptance, prioritizing drugs that may offer major advances over available therapy.

What to Discuss With Your Oncologist Now

If you have recently been diagnosed with metastatic TNBC, ask your oncologist whether your tumor has been tested for PD-L1 expression and what the result means for your first-line treatment options.
If you are PD-L1-positive and immunotherapy-eligible, pembrolizumab plus chemotherapy is the current standard of care and is not affected by this FDA decision.
If you are immunotherapy-ineligible, ask your oncologist about clinical trials for which you may be eligible, including ongoing Dato-DXd studies and other ADC programs in TNBC. ClinicalTrials.gov is the best place to search for open studies.
If Dato-DXd receives FDA approval in Q2 2026, it will immediately become available as an alternative first-line option to standard chemotherapy for immunotherapy-ineligible patients. NCCN guideline updates typically follow promptly after FDA approval.

We will update this post when the FDA issues its ruling.

For patients and families navigating a TNBC diagnosis, the most important resource is an oncologist at a center with experience in breast cancer clinical trials and access to current molecular testing. The National Cancer Institute’s Cancer Center directory can help identify specialized centers. Susan G. Komen and the Triple Negative Breast Cancer Foundation maintain updated patient-facing resources on treatment options, clinical trials, and support programs.

Sources

Primary publication: Dent RA, Shao Z, Schmid P, et al. Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial. Annals of Oncology. 2026 Apr 3. doi:10.1016/j.annonc.2026.03.008. PubMed PMID: 41937088.

OncLive Phase 3 results: TROPION-Breast02 Data Support Dato-DXd as New First-Line SOC in Triple-Negative Breast Cancer. OncLive. April 2026.

OncLive Priority Review: FDA Grants Priority Review to Frontline Dato-DXd for Metastatic TNBC Ineligible for Immunotherapy. OncLive. 2026.

OncLive panel discussion: Findings for Frontline Dato-DXd From TROPION-Breast02 in Immunotherapy-Ineligible TNBC. OncLive. May 2026.

OncoDaily safety summary: Datopotamab Deruxtecan Improves PFS and OS in First-Line Advanced TNBC in TROPION-Breast02. OncoDaily. April 2026.

Cancer Nursing Today: Datopotamab Deruxtecan Expands First-Line Treatment Options in Metastatic TNBC. May 2026.

CancerNetwork overview: How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research. CancerNetwork. May 2026.

AstraZeneca Priority Review announcement: DATROWAY granted Priority Review in the US as 1st-line treatment for patients with metastatic TNBC who are not candidates for immunotherapy. AstraZeneca. 2026.

TROPION-Breast01 context: FDA approves datopotamab deruxtecan for HR+/HER2- breast cancer. FDA.gov. January 2025.

Patient resources: NCI Cancer Center directory | Susan G. Komen | TNBC Foundation

Disclaimer: Health Evidence Digest provides general information about clinical trials and FDA regulatory processes for educational purposes. This content is not a substitute for professional medical advice. Datopotamab deruxtecan (Dato-DXd/Datroway) is not yet FDA-approved for triple-negative breast cancer. Treatment decisions for metastatic TNBC should be made in close consultation with a qualified oncologist who can account for your individual diagnosis and treatment history.

May 8, 2026

A First-of-Its-Kind Cancer Drug Is Heading Toward FDA Approval. What Is a PROTAC and What Could It Mean for Breast Cancer Treatment?

📌 Updated May 1, 2026: FDA Approval Confirmed The FDA approved vepdegestrant (Veppanu) on May 1, 2026, more than five weeks ahead of the June 5 PDUFA date. This post has been updated throughout to reflect the approval. For a companion analysis covering both this approval and the ODAC vote against camizestrant the day before, see: The FDA Said Yes to One ESR1 Drug and No to Another.

For most of the past decade, the standard treatment arc for ER-positive, HER2-negative metastatic breast cancer has followed a recognizable sequence. First-line CDK4/6 inhibitor plus endocrine therapy. Disease progression. A second endocrine therapy, often fulvestrant. Progression again. Options narrowing.

A significant portion of patients progressing on that arc carry a specific tumor mutation in the ESR1 gene that makes their cancer actively resistant to standard endocrine therapies. Their tumors have evolved to activate the estrogen receptor without estrogen. For these patients, the question is not whether the disease will progress but how much time and quality of life can be preserved between progression events.

Vepdegestrant (Veppanu), developed by Arvinas and Pfizer, was approved by the FDA on May 1, 2026. It is designed specifically for this population. What makes it scientifically distinctive is not just its efficacy data but the mechanism. Vepdegestrant is a PROTAC: a drug that destroys its target protein rather than blocking it. It is the first drug of this type ever cleared in oncology.

The ESR1 Mutation Problem: How Tumors Learn to Ignore Endocrine Therapy

ER-positive breast cancer is driven by estrogen signaling through the estrogen receptor, a protein encoded by the ESR1 gene. Standard endocrine therapies work by either suppressing estrogen production (aromatase inhibitors) or blocking estrogen from binding to the receptor (fulvestrant). This works well initially. The problem develops over time.

Under the selective pressure of prolonged endocrine therapy, tumor cells can acquire point mutations in the ligand-binding domain of ESR1, the region where estrogen normally attaches to activate the receptor. These mutations cause the receptor to adopt an active conformation even in the absence of estrogen. The tumor has effectively rewired itself to bypass the treatment. The cancer grows because it no longer needs the hormone the therapy is trying to suppress.

This is not a rare edge case. Studies show ESR1 mutations are present in approximately 20 to 40% of ER+/HER2- metastatic breast cancer patients who have received prior aromatase inhibitor therapy, and the prevalence increases substantially with treatment lines, reaching as high as 59% in ctDNA analysis of patients in later lines. The broad adoption of CDK4/6 inhibitors in combination with aromatase inhibitors as the first-line standard has actually accelerated ESR1 mutation emergence, because the CDK4/6 inhibitor extends the duration of aromatase inhibitor exposure and thus the selective pressure for ESR1 mutations.

Why ctDNA testing matters for this patient population ESR1 mutations are generally not present at initial diagnosis — they are acquired under treatment pressure. This means testing the primary tumor biopsy taken at diagnosis will miss them in most cases. Detection requires liquid biopsy (circulating tumor DNA, or ctDNA) testing on a blood sample taken after disease progression. ASCO and NCCN guidelines recommend ctDNA testing for ESR1 mutations in patients with ER+/HER2- advanced breast cancer progressing on endocrine therapy, because ESR1 mutation status now directly informs treatment selection. The FDA simultaneously approved the Guardant360 CDx as the companion diagnostic for identifying patients eligible for vepdegestrant. If you have ER+/HER2- advanced breast cancer and have not had ctDNA testing, discuss it with your oncologist.

What Is a PROTAC? The Chemistry Behind a New Era of Cancer Drugs

To understand what makes vepdegestrant different from everything that came before, it helps to understand how conventional targeted therapies work and where they fall short.

Most existing targeted therapies, aromatase inhibitors, kinase inhibitors, CDK4/6 inhibitors, work by occupying the active site of a target protein and blocking its function. The analogy often used is a key and a lock: the drug sits in the lock and prevents the key from working. The protein is inhibited but remains present.

There are two fundamental problems with this approach in cancer. First, tumors can develop mutations that change the shape of the binding site, so the inhibitor no longer fits. The protein is still there; it’s just not blocked anymore. Second, some cancer-driving proteins don’t have conveniently accessible active sites at all, making conventional inhibition impossible. These are sometimes described as “undruggable” targets, a category that has driven decades of failed drug development attempts.

The PROTAC approach: degrade instead of block

PROTAC stands for PROteolysis TArgeting Chimera. It is a bifunctional molecule: one end binds to the cancer-driving target protein (in vepdegestrant’s case, the estrogen receptor), and the other end recruits an E3 ubiquitin ligase. This ligase is part of the cell’s own protein disposal machinery, the ubiquitin-proteasome system. When both ends of the PROTAC connect their respective targets, the cell’s disposal machinery tags the cancer protein with ubiquitin chains. The tagged protein is then threaded through the proteasome, essentially a molecular shredder, and destroyed.

Once the protein is degraded, the PROTAC is released and can recruit the next copy of the target protein for destruction. This catalytic recycling means each PROTAC molecule can degrade multiple copies of the target, potentially making high drug concentrations less necessary. Because the mechanism destroys the protein rather than occupying its active site, resistance through active-site mutation is far harder. The tumor cannot mutate away from destruction the way it can mutate away from blockade.

Feature	Traditional inhibitor (e.g., fulvestrant)	PROTAC (vepdegestrant)
Mechanism	Binds to and blocks target protein function	Recruits cell’s own disposal machinery to degrade target protein entirely
Target protein after treatment	Present but inhibited	Eliminated
Resistance pathway	Active-site mutations allow escape	Harder to mutate away from degradation
Drug efficiency	Must maintain continuous occupancy (stoichiometric)	Each molecule can be recycled (catalytic)
Druggability range	Requires accessible active site	Can target proteins without conventional drug-binding pockets
Administration	Intramuscular injection (fulvestrant)	Oral, once daily (vepdegestrant)

The VERITAC-2 Trial: What the Data Shows and What It Doesn’t

The FDA approval is based on data from VERITAC-2 (NCT05654623), a global, randomized, open-label Phase 3 trial. It enrolled 624 patients with ER+/HER2- advanced or metastatic breast cancer whose disease had progressed on prior CDK4/6 inhibitor plus endocrine therapy. Patients were stratified by ESR1 mutation status and presence of visceral disease, then randomized 1:1 to receive vepdegestrant 200 mg orally once daily or fulvestrant 500 mg by intramuscular injection. VERITAC-2 data were presented at the 2025 ASCO Annual Meeting and simultaneously published in The New England Journal of Medicine.

Efficacy results

Endpoint	Vepdegestrant	Fulvestrant
ESR1-mutated subpopulation (n=270)
Median PFS (BICR)	5.0 months (95% CI 3.7 to 7.4)	2.1 months (95% CI 1.9 to 3.5)
Hazard ratio	0.58 (95% CI 0.43 to 0.78)	Reference
p-value	less than 0.001	—
Risk reduction	43%	—
Treatment ongoing at analysis	33%	12%
Overall population (ITT, n=624)
Median PFS (BICR)	3.8 months (95% CI 3.7 to 5.3)	3.6 months (95% CI 2.6 to 4.0)
Hazard ratio (ITT)	0.83 (95% CI 0.69 to 1.01)	Reference
p-value (ITT)	0.07, NOT statistically significant	—
Overall survival	Immature at analysis	—

Source: Hamilton E et al. Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer. NEJM. 2025. doi:10.1056/NEJMoa2505725

The ITT miss is the most important nuance in this dataset The VERITAC-2 trial had two primary endpoints: PFS in the ESR1-mutated subpopulation and PFS in the overall intent-to-treat (ITT) population. Vepdegestrant met the first. It did not meet the second: overall ITT PFS was 3.8 versus 3.6 months (HR 0.83, p=0.07), which missed statistical significance. This matters for how the FDA scoped the approval. The indication is specifically for patients with ESR1-mutated tumors, not all comers with ER+/HER2- advanced disease. The drug does not appear to add meaningful benefit in the absence of this mutation. This pattern has been seen before: elacestrant (Orserdu), the currently approved oral SERD for this population, similarly showed its benefit confined to the ESR1-mutated subgroup in the EMERALD trial. The biology makes sense: patients whose tumors don’t carry ESR1 mutations are progressing through other resistance mechanisms that ESR1-targeting drugs don’t address. The clinical implication is that biomarker testing is not optional here. ESR1 mutation status is the selection criterion.

Safety Profile: What the Trial Showed

Vepdegestrant was generally well tolerated, with no unexpected safety signals in VERITAC-2. The FDA label includes important warnings about QTc interval prolongation and embryo-fetal toxicity that clinicians and patients should be aware of.

Adverse Event	Vepdegestrant	Fulvestrant
Fatigue (all grade)	26.6 to 27%	16%
Elevated ALT (all grade)	14.4%	10%
Elevated AST (all grade)	14.4%	10%
Nausea (all grade)	13%	9%
Grade 3 or higher adverse events	23.4%	17.6%
Treatment discontinuation due to AEs	2.9%	0.7%
QTc prolongation	Signal present; routine monitoring required per label	Not a labeled concern
New or unexpected safety signals	None identified	—

The elevated liver enzyme findings (ALT and AST) were predominantly low-grade and did not commonly lead to discontinuation. Fatigue at 27% versus 16% is meaningfully higher than with fulvestrant and worth discussing with patients proactively. The QTc prolongation signal in the label requires routine electrocardiogram monitoring during treatment, particularly when vepdegestrant is used in combination with other QTc-prolonging agents. The 2.9% discontinuation rate due to adverse events, while slightly higher than fulvestrant’s 0.7%, remains low in absolute terms for a heavily pre-treated metastatic population.

Where Vepdegestrant Fits: The ESR1-Mutated Treatment Landscape

Vepdegestrant is not the first drug developed specifically for ESR1-mutated ER+ metastatic breast cancer, but it is the first PROTAC in this space. Understanding where it sits relative to elacestrant requires knowing the current options.

Drug	Class	FDA Status	Key Trial
Fulvestrant (Faslodex)	SERD (injection)	Approved, current standard	Multiple trials; no ESR1-specific indication
Elacestrant (Orserdu)	Oral SERD	Approved January 2023, ESR1-mutated ER+/HER2- MBC	EMERALD: PFS 2.8 vs 1.9 months (ESR1m), HR 0.55
Vepdegestrant (Veppanu)	Oral PROTAC ER degrader	Approved May 1, 2026, ESR1-mutated ER+/HER2- MBC	VERITAC-2: PFS 5.0 vs 2.1 months (ESR1m), HR 0.58

The natural comparison is to elacestrant, the only previously approved oral SERD for ESR1-mutated ER+ metastatic breast cancer. Elacestrant showed PFS of 2.8 versus 1.9 months in the ESR1-mutated population of EMERALD (HR 0.55). Vepdegestrant showed 5.0 versus 2.1 months (HR 0.58). The numerics look more favorable for vepdegestrant, but these are separate trials with different patient populations, different prior treatment histories, and different control arms. Cross-trial comparisons are unreliable and should not be used to conclude one drug is superior to the other. No head-to-head trial exists.

What the landscape now offers is two approved oral options in the ESR1-mutated second-line setting, with different mechanisms and safety profiles. The sequencing question — which drug to use in which patient, and what comes after progression on either — is one the field will be working through over the next several years as real-world experience accumulates.

For a detailed analysis of how the vepdegestrant approval compares to the same-day ODAC vote against camizestrant, and what both decisions reveal about ctDNA-guided treatment strategies, see our post: The FDA Said Yes to One ESR1 Drug and No to Another.

Beyond Vepdegestrant: Why a PROTAC Approval Matters for All of Cancer Medicine

The significance of vepdegestrant’s approval extends well beyond this particular drug and patient population. Dozens of PROTAC candidates are currently in clinical development for a range of cancers, and this first approval validates the entire platform in a way that decades of academic research could not.

The PROTAC approach is particularly promising for what oncologists call “undruggable” targets, proteins that drive cancer growth but don’t have accessible pockets for conventional inhibitors. Mutant KRAS, certain transcription factors, and specific fusion proteins have resisted decades of drug development attempts. PROTAC-based degradation sidesteps the binding-site requirement, potentially making these targets approachable for the first time.

In breast cancer specifically, ongoing trials are exploring vepdegestrant in combination with CDK4/6 inhibitors. The VERITAC-1 Phase 1/2 study established tolerability for the vepdegestrant plus palbociclib combination. If vepdegestrant demonstrates durable benefit in combination regimens, the scope of its utility could expand significantly beyond the current second-line monotherapy setting.

What This Means for Patients Right Now

Vepdegestrant (Veppanu) is now FDA-approved and commercially available. Here is what patients navigating ER+/HER2- metastatic breast cancer should know:

If you have ER+/HER2- metastatic breast cancer and have progressed on CDK4/6 inhibitor-based therapy: ask your oncologist whether your tumor has been tested for ESR1 mutations via ctDNA liquid biopsy. This is increasingly the standard of care and directly affects which therapies are appropriate. The Guardant360 CDx is the FDA-approved companion diagnostic for this indication.
If you already have an ESR1 mutation documented: both elacestrant (Orserdu) and vepdegestrant (Veppanu) are now approved options in this setting. Discuss with your oncologist which is appropriate for your situation.
If you are in earlier lines of treatment: vepdegestrant is specifically approved for patients who have already received CDK4/6 inhibitor plus endocrine therapy. It is not a first-line option.
Do not wait to have the ESR1 testing conversation. Whether or not you are currently considering vepdegestrant, ESR1 mutation status is clinically actionable today because of both approved agents.

The treatment landscape for ER+/HER2- metastatic breast cancer is evolving faster than at any point in the past decade. The key resources for staying current include NCCN Clinical Practice Guidelines, the Metastatic Breast Cancer Alliance, and Living Beyond Breast Cancer, which maintains patient-facing resources on ESR1 mutations, ctDNA testing, and treatment options in the endocrine-resistant setting.

Sources

FDA approval: FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. FDA.gov. May 1, 2026.

NEJM primary publication: Hamilton E et al. Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer. New England Journal of Medicine. 2025. doi:10.1056/NEJMoa2505725

VERITAC-2 trial registration: NCT05654623. ClinicalTrials.gov.

Arvinas FDA approval announcement: Arvinas Announces FDA Approval of VEPPANU (vepdegestrant). GlobeNewswire. May 1, 2026.

AJMC approval coverage: FDA Approves Vepdegestrant for ESR1-Mutated, ER-Positive, HER2-Negative Advanced Breast Cancer. AJMC. May 2026.

VERITAC-2 study design (PMC): VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer. PMC11524203.

ESR1 mutation prevalence: Comprehensive genomic profiling of ESR1 in HR+/HER2- MBC. PMC11420341.

Nature Reviews Clinical Oncology: PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER+HER2- breast cancer harbouring acquired ESR1 mutations. Nat Rev Clin Oncol. 2025. doi:10.1038/s41571-025-01062-6

Elacestrant FDA approval: FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated breast cancer. FDA.gov. January 2023.

Patient resources: NCCN Guidelines | MBC Alliance | Living Beyond Breast Cancer | Guardant360 CDx information

Disclaimer: Health Evidence Digest provides general information about clinical trials and FDA regulatory processes for educational purposes. This content is not a substitute for professional medical advice. Treatment decisions for metastatic breast cancer should be made in close consultation with a qualified oncologist who can account for your individual diagnosis, tumor characteristics, and treatment history.

May 5, 2026

You May Be Able to Test Yourself for Cervical Cancer Risk. New 2026 Screening Guidelines Explained.

📌 The key update at a glance On January 5, 2026, updated Women’s Preventive Services Guidelines added self-collection as a recognized option for cervical cancer screening. Women ages 30 to 65 at average risk can now collect their own vaginal sample for high-risk HPV (hrHPV) testing without a clinician-performed pelvic exam. hrHPV testing is designated as the preferred screening approach for this age group. The update was published in JAMA and is effective immediately. A companion insurance coverage requirement covering follow-up testing after a positive result takes effect January 1, 2027. This post explains what changed, who it applies to, and what to do now.

Cervical cancer is one of the most preventable cancers we have. Screening works. The HPV vaccine works. And yet, in the United States, roughly 13,000 women are diagnosed with cervical cancer each year, and about 4,000 die from it. Most of those women were either never screened or hadn’t been screened recently enough.

The barriers are real: no insurance, no regular doctor, not enough time, anxiety about pelvic exams, or living too far from a clinic that offers them. For a lot of women, the Pap smear is not inaccessible in theory. It’s inaccessible in practice.

New guidelines published on January 5, 2026, updated the Women’s Preventive Services Guidelines to include self-collection as an option for cervical cancer screening. Women ages 30 to 65 at average risk can now collect their own vaginal sample for hrHPV testing. The update was published in JAMA and is effective immediately.

Here is what the updated guidelines actually say, what the science behind HPV-based screening shows, and what this change means in practical terms for women who are overdue for screening.

What Changed: The Key Updates in Plain Language

The updated HRSA guideline designates high-risk HPV (hrHPV) testing as the preferred screening modality for average-risk women ages 30 to 65, whether collected by the patient or a clinician, while retaining the option for cervical cytology (Pap) testing. For average-risk women ages 21 to 29, cervical cancer screening using cervical cytology remains the recommendation. No change for that group.

The insurance coverage piece is equally significant. The guideline includes new language requiring most insurance plans to cover any additional testing needed to complete the screening process after an abnormal result, with coverage beginning January 1, 2027.

What Changed in the January 2026 HRSA Update	What It Means for Patients
Self-collection is now a recognized option for average-risk women ages 30 to 65	You can collect your own vaginal sample for hrHPV testing without a clinician-performed pelvic exam
hrHPV testing designated as preferred screening method for women ages 30 to 65	HPV testing every 5 years is the primary recommended approach for this age group; the Pap remains available
Women ages 21 to 29 continue to screen with Pap smear every 3 years	No change for this age group
Insurance coverage for follow-up testing required from January 1, 2027	Colposcopy, biopsy, and follow-up after an abnormal result will be required to be covered by most plans

A note on guideline bodies: The American Cancer Society has separately recommended hrHPV-primary screening starting at age 25 since 2020. That is existing guidance, not a 2026 change. The January 2026 HRSA update discussed throughout this post applies specifically to women ages 30 to 65. If you are between 25 and 29, ask your provider about hrHPV testing options, because your age group sits at the intersection of two different guideline recommendations.

Why HPV Testing Instead of the Pap Smear?

This is worth understanding, because many women are more familiar with the Pap smear, and the shift to HPV-primary screening is not just a convenience update. It reflects a genuinely better test for this purpose.

Cervical cancer is caused almost entirely by persistent infection with high-risk strains of human papillomavirus (HPV). Not every HPV infection causes cancer; most clear on their own. But when certain high-risk strains (HPV 16 and 18 are the most dangerous) persist in cervical cells over time, they can trigger changes that progress to cancer if not detected and treated.

The Pap smear detects abnormal cell changes that have already happened. HPV testing detects the underlying viral cause before those changes necessarily occur. This is why HPV testing catches more cases earlier, generates fewer false negatives, and allows for longer intervals between screenings.

Test	What It Detects	Screening Interval	Sensitivity for CIN2+	Self-Collection Validated?
Pap smear (cytology)	Abnormal cervical cells	Every 3 years (ages 21 to 65)	~55 to 60%	No, clinician collection required
hrHPV test alone	High-risk HPV strains	Every 5 years (ages 25 to 65 per ACS; 30 to 65 per HRSA)	~90 to 95%	Yes
Co-test (Pap + HPV)	Both	Every 5 years (ages 30 to 65)	High	Partial

Sensitivity estimates for CIN2+ detection based on meta-analyses including Koliopoulos et al., Cochrane Database of Systematic Reviews, 2017 and subsequent validation studies.

How Self-Collection Works

Self-collected samples for HPV testing use a vaginal swab, not a cervical swab. This is an important distinction. You are not performing a Pap smear on yourself. You are collecting cells from the vaginal wall, which also carry HPV and have been validated in extensive research as an accurate way to detect high-risk strains.

In clinical validation studies, self-collected vaginal samples detect high-risk HPV with sensitivity comparable to clinician-collected cervical samples, particularly for detecting CIN2+ (the precancerous cell changes that matter most for preventing cancer).

How it works in practice:

A self-collection kit contains a vaginal swab, similar in size and feel to a tampon applicator.
You insert the swab a few inches into the vagina, rotate it, and remove it.
The swab is sealed in the provided container and either mailed to a lab or returned to a clinic.
The sample is tested for high-risk HPV strains.

Most women describe the process as quick and straightforward. No speculum. No stirrups. No need to undress.

Self-collection kits are not yet universally available through all U.S. healthcare systems. The 2026 guidelines establish the framework, but distribution will expand over time. The insurance coverage requirement starting in 2027 is expected to accelerate availability.

Who These Guidelines Apply To

Women ages 30 to 65 at average risk are the primary group for whom self-collection is now a recognized option. “Average risk” means no history of high-grade cervical precancer or cervical cancer, no immunocompromising conditions such as HIV, and no prior DES exposure in utero.

Women ages 21 to 29: No change. Pap smear every 3 years remains the recommendation. Self-collection is not recommended for this group because HPV infections in younger women are more commonly transient, and the Pap smear, which detects actual cell changes, is more clinically actionable for this age group.

Women ages 25 to 29, a note on the ACS guideline: The American Cancer Society’s preferred approach recommends hrHPV-primary testing starting at age 25. If you are in this age range and interested in HPV testing rather than a Pap smear, talk to your provider. The 2026 HRSA update does not cover this group for self-collection, but the ACS guideline supports HPV-primary screening beginning at 25 with clinician-collected samples.

Women with higher-than-average risk (HIV, history of cervical cancer, immunosuppression) require individualized schedules. These general guidelines do not apply to them.

Women who have had a hysterectomy that removed the cervix and have no history of cervical cancer or high-grade lesions generally do not need routine cervical cancer screening. Confirm with your provider.

What About the Insurance Coverage Change?

Previously, most insurance plans covered the initial screening test at no cost under the ACA. But if that test came back abnormal and required follow-up, such as a colposcopy, genotyping, or biopsy, patients often owed cost-sharing for those procedures. This created a situation where the screening was free but the follow-up it triggered was not, and some women skipped follow-up care as a result.

The updated guideline now includes language requiring most insurance plans to cover the additional testing needed to complete the screening process, with coverage beginning January 1, 2027.

This removes a key financial barrier. If your hrHPV test comes back positive, you should no longer face unexpected bills for the colposcopy or biopsy it necessitates, at least not starting next year.

Why This Matters for Screening Equity

Cervical cancer rates in the United States are not evenly distributed. Black women and Hispanic women have higher cervical cancer incidence and mortality rates than white women. Women in rural areas and women without a primary care provider are less likely to be up to date on screening.

Self-collection directly addresses several of these gaps. It removes the requirement for a clinical pelvic exam, which is a barrier for women who have experienced trauma, women who avoid clinical settings for cultural reasons, and women in areas with provider shortages. It enables screening to happen at home, through mailed kits, at community health events, or in non-clinical settings.

Research supports this. Studies in underscreened populations have consistently found that offering self-collection substantially increases participation. In some analyses, uptake increased by more than double compared to standard clinic-based reminders alone.

This guideline change is part of a broader shift in women’s health toward evidence-based updates that close access gaps. The same pattern is visible in other areas: earlier this year, ACOG updated its diagnostic guidance for endometriosis to remove the requirement for surgical confirmation before treatment begins, reducing barriers for women who had been undertreated for years. We covered that development and what it means for the endometriosis treatment pipeline here.

A Note on the HPV Vaccine

Screening guidelines are separate from vaccination, but they are part of the same prevention story. The HPV vaccine (Gardasil 9) protects against the high-risk strains most likely to cause cervical cancer. It is recommended for all children at age 11 or 12, teens and young adults through age 26 who were not vaccinated earlier, and adults ages 27 to 45 on a shared decision-making basis.

Vaccination does not eliminate the need for screening. Even vaccinated women should continue following cervical cancer screening guidelines, because the vaccine does not protect against all HPV strains and does not help those who were already infected before vaccination.

What to Do Now

If you are a woman between 30 and 65 and have not been screened in the last 5 years, this is the right moment.

Contact your primary care provider or OB-GYN and ask about hrHPV testing, including whether self-collection is available through their practice.
If you don’t have a regular provider, community health centers offer cervical cancer screening regardless of insurance status.
Ask specifically about self-collection kits. Availability is expanding but not yet universal.
If you are ages 21 to 29, follow the current Pap smear recommendation: every 3 years.
If your test comes back positive, follow up. Starting in 2027, most insurance plans are required to cover that follow-up testing.

Quick Reference: 2026 Cervical Cancer Screening by Age

Age group	Recommendation
Ages 21 to 29	Pap smear every 3 years. Self-collection not recommended.
Ages 25 to 29 (ACS guideline)	hrHPV testing every 5 years with clinician-collected sample is the ACS preferred approach. Discuss with your provider.
Ages 30 to 65 (HRSA 2026 update)	hrHPV testing every 5 years. Self-collection now a recognized option.
Ages 30 to 65 (alternative)	Pap + HPV co-test every 5 years, or Pap alone every 3 years.
Over 65	May be able to stop if adequately screened in the prior 10 years. Confirm with provider.

Sources

HRSA press release: New Cervical Cancer Screening Guidelines Strengthen Women’s Preventive Health. January 5, 2026.

Federal Register: Update to the Women’s Preventive Services Guidelines. January 5, 2026.

JAMA publication: jamanetwork.com/journals/jama/fullarticle/2843501

AACR Blog: Updated Guidelines Can Help Make Cervical Cancer Screening and HPV Vaccination More Convenient. January 12, 2026.

American Cancer Society guidelines: cancer.org/cancer/types/cervical-cancer

Sensitivity data: Koliopoulos G, et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database of Systematic Reviews. 2017.

Find a health center: findahealthcenter.hrsa.gov

Disclaimer: Health Evidence Digest provides general information about screening guideline updates and health research for educational purposes. This content is not a substitute for professional medical advice. Cervical cancer screening decisions should be made in consultation with a qualified healthcare provider based on your individual health history.

May 4, 2026

A Historic First: FDA Approves Immunotherapy for Platinum-Resistant Ovarian Cancer — What the KEYNOTE-B96 Data Tells Us

📌 The essentials On February 10, 2026, the FDA approved pembrolizumab (Keytruda, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (combined positive score, or CPS, of at least 1). The approval covers patients who have received one or two prior lines of systemic therapy. This is the first FDA-approved immunotherapy for ovarian cancer in history. The clinical basis: KEYNOTE-B96/ENGOT-ov65 (NCT05116189), a randomized, double-blind, placebo-controlled Phase 3 trial in 643 patients, showed median overall survival of 18.2 months versus 14.0 months with placebo (HR 0.76; p=0.0053) in the PD-L1 CPS of 1 or higher population. The first statistically significant OS benefit ever demonstrated by an immune checkpoint inhibitor in ovarian cancer. A companion diagnostic requirement: Tumor testing with the PD-L1 IHC 22C3 pharmDx assay confirming CPS of 1 or higher is required before treatment. This is a requirement, not a recommendation.

Ovarian cancer has resisted immunotherapy for decades. Every major trial of immune checkpoint inhibitors in this disease came back negative or borderline, results that didn’t survive longer follow-up. The field watched other gynecologic cancers, particularly cervical and endometrial, respond to PD-1 blockade while ovarian cancer remained stubbornly outside that story.

That changed on February 10, 2026.

The FDA approved pembrolizumab (Keytruda, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS of at least 1). The approval covers patients who have received one or two prior lines of systemic therapy.

It is the first FDA-approved immunotherapy for ovarian cancer in history.

This post covers what platinum resistance means and why it matters, what KEYNOTE-B96 showed across its primary and key secondary endpoints, how to read the survival data carefully, what the companion diagnostic approval means in practice, and what questions are still open.

Platinum Resistance: Why This Setting Is So Hard to Treat

Most women with advanced ovarian cancer respond well to their first-line treatment, typically surgery followed by platinum-based chemotherapy, often combined with a taxane and increasingly with PARP inhibitors as maintenance. Response rates in the frontline setting can exceed 70 to 80%.

The problem is recurrence. About 70 to 80% of patients with advanced ovarian cancer relapse after initial treatment. When recurrence happens, the most important prognostic factor is how quickly it occurs after the last platinum therapy. Patients whose disease progresses more than six months after platinum are classified as platinum-sensitive and can be retreated with platinum. Patients whose disease progresses within six months are classified as platinum-resistant.

Platinum resistance is a watershed moment in the treatment arc. Non-platinum options, including weekly paclitaxel, pegylated liposomal doxorubicin, gemcitabine, and bevacizumab, produce response rates in the 10 to 20% range and median progression-free survival measured in months. Median overall survival in platinum-resistant ovarian cancer has historically ranged from roughly 12 to 16 months. These patients carry significant unmet need, and the disease is hard to control with anything currently available.

That is the context in which the KEYNOTE-B96 results need to be understood.

The KEYNOTE-B96 Trial: Design and Patient Population

KEYNOTE-B96 (also known as ENGOT-ov65, NCT05116189) was a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial enrolling 643 patients with histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Eligibility required:

Platinum-resistant disease, defined as radiographic progression within six months of the last platinum-based regimen
One or two prior lines of systemic therapy for ovarian carcinoma
At least one prior platinum-based chemotherapy regimen
Measurable disease by RECIST v1.1

Patients with primary platinum-refractory disease, meaning progression during or immediately after first-line platinum, were excluded.

Patients were randomized 1:1 to pembrolizumab plus weekly paclitaxel (80 mg/m² on days 1, 8, and 15 of each 3-week cycle), with or without bevacizumab (10 mg/kg every two weeks), or placebo plus the same backbone. Bevacizumab use was at investigator’s discretion and was a stratification factor. Stratification also included geographic region and PD-L1 expression by CPS.

The primary endpoint was investigator-assessed progression-free survival (PFS) by RECIST v1.1, evaluated first in the PD-L1 CPS of 1 or higher population, then in the ITT population. Overall survival was a key secondary endpoint.

What is PD-L1 CPS and why does it determine eligibility? PD-L1 Combined Positive Score (CPS) measures PD-L1 protein expression across tumor cells, tumor-associated lymphocytes, and macrophages. A CPS of 1 or higher means at least 1 PD-L1-staining cell per 100 tumor cells was detected. This is a relatively low threshold: in KEYNOTE-B96, approximately 466 of 643 patients (roughly 72%) had CPS of 1 or higher. The FDA approval is restricted to CPS of 1 or higher patients, where both PFS and OS benefits were demonstrated. The ITT population also showed significant PFS improvement, but the OS benefit was most clearly established in the CPS of 1 or higher group. This matters in practice: before receiving this regimen, a patient’s tumor must be tested with the FDA-approved companion diagnostic, the PD-L1 IHC 22C3 pharmDx assay, and return a CPS of 1 or higher result. This is a requirement, not a recommendation.

The Results: Progression-Free Survival and Overall Survival

The trial conducted two pre-specified interim analyses. The second (IA2), with a data cutoff of May 5, 2025, was presented at ESMO Congress 2025 in Berlin in October 2025 and formed the basis for the February 2026 FDA approval. Final OS data were subsequently published in The Lancet in April 2026.

Progression-Free Survival

In the PD-L1 CPS of 1 or higher population (n=466), median PFS was 8.3 months with pembrolizumab versus 7.2 months with placebo, with a hazard ratio of 0.72 (95% CI 0.58 to 0.89; p=0.0014). The 12-month PFS rate was 35.2% for pembrolizumab versus 22.6% for placebo.

In the ITT population (all 643 patients), median PFS was 8.3 versus 6.4 months (HR 0.70; 95% CI 0.58 to 0.84; p less than 0.0001), with 12-month PFS rates of 33.1% versus 21.3%.

These are statistically significant and clinically meaningful improvements in a setting where six months of progression-free survival is often considered a reasonable benchmark.

Overall Survival

Among the 466 PD-L1 CPS of 1 or higher patients, median OS was 18.2 months in the pembrolizumab arm versus 14.0 months with placebo, a hazard ratio of 0.76 (95% CI 0.61 to 0.94; p=0.0053). The 12-month OS rate was 69.1% versus 59.3%. The 18-month OS rate was 51.5% versus 38.9%.

A four-month improvement in median OS. The first statistically significant overall survival benefit ever shown by an immune checkpoint inhibitor in ovarian cancer.

Endpoint	Pembrolizumab plus chemo	Placebo plus chemo	HR (95% CI)	P-value
Median PFS (CPS of 1 or higher)	8.3 months	7.2 months	0.72 (0.58 to 0.89)	0.0014
Median PFS (ITT)	8.3 months	6.4 months	0.70 (0.58 to 0.84)	less than 0.0001
Median OS (CPS of 1 or higher)	18.2 months	14.0 months	0.76 (0.61 to 0.94)	0.0053
12-month OS (CPS of 1 or higher)	69.1%	59.3%	—	—
18-month OS (CPS of 1 or higher)	51.5%	38.9%	—	—

Source: KEYNOTE-B96/ENGOT-ov65 Phase 3 trial, IA2 (data cutoff May 5, 2025). Final OS data: The Lancet, April 2026. FDA approval: February 10, 2026.

How to Read These Numbers Carefully

A four-month improvement in median OS is real and clinically meaningful in this setting, particularly given the historical absence of any survival benefit from immunotherapy in ovarian cancer. But it is worth understanding what the numbers do and don’t tell us.

The hazard ratio of 0.76 means that at any given point during the trial, patients in the pembrolizumab arm had a 24% lower risk of death than those in the placebo arm. This is not a cure. It is a reduction in the rate of events that translates into prolonged survival for a meaningful portion of patients. The 18-month OS rate shifting from 38.9% to 51.5% is the clearest way to see this: at 18 months, roughly one in eight additional patients were alive in the pembrolizumab arm compared to the placebo arm.

The approval is restricted to CPS of 1 or higher. About 72% of patients in KEYNOTE-B96 met this threshold, so most platinum-resistant ovarian cancer patients would be eligible for testing, but not all will test positive.

Median survival describes the midpoint of the distribution, not individual patient outcomes. Some patients in the pembrolizumab arm had substantially longer survival than 18 months. The final OS data from The Lancet publication provides a clearer view of the tail of the survival curve, which will help clarify whether there is a subset of patients with especially durable benefit, the pattern that checkpoint inhibitors sometimes produce in other tumors.

The Companion Diagnostic: What the PD-L1 Test Means in Practice

The FDA simultaneously approved the PD-L1 IHC 22C3 pharmDx assay (Agilent Technologies) as a companion diagnostic for identifying eligible patients. Tumor PD-L1 testing confirming CPS of 1 or higher is required before treatment, not optional.

The 22C3 pharmDx assay is the same companion diagnostic used in pembrolizumab approvals across multiple other tumor types, including cervical, endometrial, esophageal, and gastric cancers. At most academic medical centers and major oncology practices, this test is already part of the standard pathology workflow. At community oncology centers or in lower-resource settings, access to and turnaround time on the assay is a practical consideration worth discussing with the treating team.

Tumor tissue for PD-L1 testing can come from the original diagnosis or a recurrence biopsy. Given that PD-L1 expression can change with disease progression, some oncologists may prefer more recently collected tissue, though the label does not mandate this.

What about bevacizumab? The approved regimen is pembrolizumab plus paclitaxel, with or without bevacizumab. Bevacizumab (Avastin) is an anti-VEGF antibody with established activity in ovarian cancer, including in the platinum-resistant setting. Its use in KEYNOTE-B96 was at investigator discretion and was a stratification factor. Patients with contraindications to anti-VEGF therapy, such as certain cardiovascular risk factors, recent major surgery, a history of GI perforation, or significant proteinuria, can receive pembrolizumab plus paclitaxel without bevacizumab. Review the full Keytruda prescribing information for complete contraindication guidance.

Why Previous Immunotherapy Trials in Ovarian Cancer Failed, and Why This One Didn’t

The history of checkpoint inhibitor trials in ovarian cancer before KEYNOTE-B96 is largely a story of negative results. Earlier Phase 3 trials, including atezolizumab plus chemotherapy in frontline and maintenance settings, did not demonstrate meaningful survival improvements. Single-agent anti-PD-1 trials showed modest response rates of 10 to 15% in unselected ovarian cancer patients.

Several factors likely contributed. Ovarian cancer has a relatively immunosuppressive tumor microenvironment, with high regulatory T cell infiltration, immunosuppressive cytokines, and ascites fluid that dampens immune activity. Tumor mutational burden is generally lower than in cancers like melanoma or lung cancer that respond robustly to checkpoint inhibitors. And earlier trials often did not select for PD-L1 expression.

KEYNOTE-B96 made design choices that may have improved its chances. The combination with weekly paclitaxel, a metronomic dosing schedule thought to have immunomodulatory properties alongside its cytotoxic effects, may have made the tumor microenvironment more permissive to immune infiltration. The CPS of 1 or higher selection enriched for a more immunologically accessible population. These are mechanistic hypotheses with biological plausibility, not proven causal explanations, but they provide a rational basis for why this combination in this specific population succeeded where broader efforts did not.

Safety: What Patients and Clinicians Need to Know

The safety profile of the pembrolizumab combination in KEYNOTE-B96 was consistent with prior pembrolizumab trials. No new safety signals were identified.

Pembrolizumab carries immune-mediated adverse reactions as a class, the consequence of broadly activating the immune system. These can affect virtually any organ system.

Key immune-mediated risks:

Pneumonitis: inflammation of the lungs; monitor for new or worsening respiratory symptoms
Colitis: diarrhea and abdominal pain; may require corticosteroids or discontinuation
Hepatitis: elevated liver enzymes; regular LFT monitoring during treatment
Endocrinopathies: thyroid dysfunction, adrenal insufficiency, type 1 diabetes mellitus, hypophysitis
Nephritis: elevated creatinine; monitor renal function
Dermatologic reactions: rash, rare severe skin reactions including Stevens-Johnson syndrome

Most immune-mediated adverse reactions are manageable with corticosteroids if caught early. The prescribing information outlines detailed management algorithms, including when to hold versus permanently discontinue pembrolizumab.

Other warnings:

Infusion-related reactions: fever, chills, hypotension, and bronchospasm are possible. Standard premedication and monitoring protocols apply.

Embryo-fetal toxicity: pembrolizumab can cause fetal harm. Women of reproductive potential should use effective contraception during treatment and for at least four months after the final dose.

Dosing:

The approved pembrolizumab dose is 200 mg IV every three weeks or 400 mg IV every six weeks, until disease progression, unacceptable toxicity, or up to 24 months of treatment. Pembrolizumab is administered before paclitaxel and bevacizumab when given on the same day.

Keytruda Qlex, a subcutaneous formulation combining pembrolizumab with berahyaluronidase alfa-pmph, was also approved. The subcutaneous dose is 395 mg/4,800 units every three weeks or 790 mg/9,600 units every six weeks, and can be administered in approximately five to ten minutes rather than the 30-minute IV infusion. For patients receiving multiple cycles over months of treatment, this is a real reduction in clinic time.

Open Questions and the Road Ahead

The KEYNOTE-B96 approval opens a new chapter in ovarian cancer treatment, but several clinical questions will shape how the approval is used in practice.

How durable is the benefit?

The final OS data in The Lancet provides longer follow-up than the interim analysis. The field will be watching for a favorable tail on the survival curve, the pattern suggesting a subset of patients achieve especially prolonged disease control, which checkpoint inhibitors produce in some tumor types.

Does PD-L1 CPS fully capture who responds?

CPS of 1 or higher is a broad threshold. Within the PD-L1-positive population there is likely meaningful heterogeneity in response. Future work will examine whether higher CPS thresholds, tumor mutational burden, microsatellite instability status, or tumor-infiltrating lymphocyte density can further refine patient selection.

What about earlier lines of therapy?

The positive KEYNOTE-B96 result will prompt investigators to ask whether pembrolizumab-containing regimens have a role in the frontline or maintenance setting in ovarian cancer. Several trials are already exploring this. The data in those settings will need to be evaluated on their own terms.

Sequencing after progression on this regimen:

The approval covers patients after one or two prior regimens. What comes next for patients who progress on pembrolizumab plus chemotherapy? The treatment landscape at third or later lines remains difficult, and ongoing trials will need to address sequencing questions. ClinicalTrials.gov is the primary resource for identifying open studies.

Project Orbis: A Global Review Pathway This approval was reviewed under Project Orbis, an FDA Oncology Center of Excellence initiative enabling concurrent submission and review across multiple international regulatory agencies. For KEYNOTE-B96, FDA collaborated with Australia’s Therapeutic Goods Administration, Health Canada, and Switzerland’s Swissmedic. Project Orbis doesn’t mean all countries approve simultaneously; each agency makes its own decision. But it creates a framework for data sharing that can accelerate global access. The designation signals that review is underway or completed in partner countries.

What This Means for Patients With Platinum-Resistant Ovarian Cancer

For patients who have progressed after one or two lines of therapy and are now facing platinum-resistant disease, the conversation with their oncologist includes a genuinely new option for the first time. Pembrolizumab plus paclitaxel, with or without bevacizumab, is not a marginal refinement. It is the first regimen to improve overall survival in this population in a Phase 3 trial.

The first step is PD-L1 testing. Patients whose disease has not been recently biopsied may want to discuss with their oncologist whether fresh tissue for biomarker testing is feasible and clinically appropriate at the time of progression.

For related coverage of how immunotherapy and ADC approvals are expanding across gynecologic and breast cancers in 2026, see our posts on Dato-DXd in triple-negative breast cancer, vepdegestrant and the first PROTAC approval in oncology, and what the FDA’s contrasting decisions on camizestrant and vepdegestrant reveal about the future of ESR1-guided treatment.

Patient advocacy organizations with resources for ovarian cancer include the Ovarian Cancer Research Alliance, the National Ovarian Cancer Coalition, and the Foundation for Women’s Cancer. All three maintain clinical trial databases and physician directories. Patients interested in trials evaluating pembrolizumab in earlier-line ovarian cancer settings can search for open studies at ClinicalTrials.gov.

Sources

FDA approval: FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma. February 10, 2026. FDA.gov.

KEYNOTE-B96 trial registration: NCT05116189. ClinicalTrials.gov.

ESMO 2025 abstract: Colombo N et al. Pembrolizumab vs Placebo Plus Weekly Paclitaxel plus/minus Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer. LBA3. ESMO Congress 2025, Berlin, October 2025.

Final OS publication: KEYNOTE-B96/ENGOT-ov65 final overall survival analysis. The Lancet. April 2026.

Merck press release: Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival. May 2025. merck.com.

OncLive approval coverage: KEYNOTE-B96 Approval Reinforces the Shift Toward Biomarker-Driven Treatment in Recurrent PROC. OncLive. March 2026.

Clinical review: The role of chemo-immunotherapy in platinum-resistant ovarian cancer in light of the KEYNOTE-B96 trial. PubMed Central.

Keytruda prescribing information: Keytruda (pembrolizumab) and Keytruda Qlex Prescribing Information. Merck. 2026.

Keytruda Qlex FDA approval: FDA approves pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for multiple indications.

Companion diagnostic: PD-L1 IHC 22C3 pharmDx. FDA list of cleared or approved companion diagnostics.

Project Orbis: Project Orbis. FDA Oncology Center of Excellence.